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Abstract 
Introduction and Objectives: The PDGFβ receptor and its ligand, PDGF-BB, are expressed 
throughout the central nervous system (CNS), including the hippocampas. Several reports confirm 
that PDGFβ receptors are neuroprotective against N-methyl-D-asparate (NMDA)-induced cell death 
in hippocampal neurons. NMDA receptor dysfunction is important for the expression of many 
symptoms of mental health disorders such as schizophrenia. 
The serotonin (5-HT) type 7 receptor was the most recent of the 5-HT receptor family to be identified 
and cloned. 5-HT receptors interact with several signaling systems in the CNS including receptors 
activated by the excitatory neurotransmitter glutamate such as the NMDA receptor. Although there is 
extensive interest in targeting the 5-HT7 receptor with novel therapeutic compounds, the function and 
signaling properties of 5-HT7 receptors in neurons remains poorly characterized.  
Methods: The SH-SY5Y neuroblastoma cell line, primary hippocampal cultures, and hippocampal 
slices were treated with 5-HT7 receptor agonists and antagonists. Western blotting was used to 
measure PDGFß receptor expression and phosphorylation as well as NMDA receptor subunit 
expression and phosphorylation levels. Real-time RT-PCR was used to measure mRNA level of 
PDGFß receptor in neuronal cultures. Cell death assays (MAP2, MTT) were used to measure the 
neuroprotective effects of 5-HT7 and PDGFß receptor activation.  
Results: My research involved elucidating the molecular mechanisms of neuroprotection after 5-HT7-
induced PDGFß receptor upregulation. I demonstrated that 24 h treatment with the selective 5-HT7 
receptor agonist, LP 12, increased not only the expression but also the activation of PDGFß receptors 
as measured by the phosphorylation of tyrosine 1021, the phospholipase Cγ binding site. Activation 
of the 5-HT7 receptor also selectively changed the expression and phosphorylation state of the NR2B 
	  	   	   iv 
subunit of the NMDA receptor. Activation of 5-HT7 receptors was neuroprotective against NMDA-
induced toxicity in primary hippocampal neurons and this effect required PDGFß receptor kinase 
activity. Thus, long-term (24 h) activation of 5-HT7 receptors was neuroprotective via increasing the 
expression of a negative regulator of NMDA activity, the PDGFß receptor. In contrast, acute 
activation (5-30 min) of 5-HT7 receptor increased NMDA evoked current and altered NMDA 
receptor subunit phosphorylation in hippocampal neurons in a manner that was different from what 
we observed in our 24 h experiments. 
Conclusions: I identified two 5-HT7 receptor to NMDA receptor pathways: acute activation of the 
receptor increased NMDA-evoked currents whereas long-term 5-HT7 agonist treatment prevented 
NMDA-induced excitotoxicity in a PDGFß receptor-dependent manner. This research is significant in 
the ongoing advances for the treatment of mental heath disorders, such as schizophrenia and 
depression, that involve the 5-HT, glutamate, and neuronal growth factor systems. 
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Chapter 1 
General Introduction 
The most complex organ in the body is the brain, whose complexity and processing depends on 
the interactions between billions of neurons. The most common method of communication 
between brain cells occurs through the actions of transmembrane receptors and neurotransmitters 
(organic chemicals released from neurons). Transmembrane protein receptors are activated upon 
binding with a chemical signal or ligand. The activation of a receptor by a ligand changes 
intracellular chemical levels (second messengers) that initiate several signaling pathways, which 
collectively result in changes in cellular responses. There are three main classes of 
transmembrane receptors: ion channels, G protein-coupled receptors (GPCRs), and receptor 
tyrosine kinases (Hazell et al. 2012). 
GPCRs are one of the largest classes of cell surface receptors (Hino et al. 2012) and contain 
seven putative hydrophobic transmembrane domains connected by three intracellular loops and 
three extracellular loops (Raymond et al. 2001). The extracellular GPCR domains consist of 
glycosylated amino termini that contain cysteine residues while the intracellular carboxyl termini 
contain sites for G-protein and regulatory proteins interaction as well as phosphorylation sites 
recognized by serine-threonine kinases (Raymond et al. 2001). G proteins, or guanosine 
nucleotide-binding proteins, are able to bind both guanosine triphosphate (GTP) and guanosine 
diphosphate (GDP) and possess intrinsic GTPase activity that slowly hydrolyzes bound GTP to 
GDP (Brown and Sihra 2008). In the inactive state, GDP is bound to the α subunit, and the α 
subunit is associated with β and γ subunits (forming a “heterotrimeric” G protein) as well as the 
GPCR. The binding of an agonist to the GPCR results in a conformational change that stimulates 
the α subunit to exchange GDP for GTP. Gα –GTP then dissociates from both the receptor and 
the Gβγ subunits, and both Gα –GTP and Gβγ are then able to interact with effector proteins 
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(Peng et al. 2003). G protein effectors include adenylyl cyclases (AC), phospholipase (PLC), Ca2+ 
channels, and several others. The intrinstic GTPase activity of the α subunit hydrolyzes GTP to 
GDP, and the α subunit reassembles with the βγ subunits to reform the heterotimer and to 
reassociate with the GPCR (Rasmussen and Habermas 2011). There are three major types of Gα 
subunits that differentially affect second messengers and signaling pathways: Gαs (stimulates 
AC), Gαi/o (inhibits AC), and Gαq (activates PLCβ). 
1.1 Serotonin receptors 
Rapport et al. discovered serotonin (5-HT, 5-hydroxytryptamine) in 1948 (Rapport et al. 1948; 
Raymond et al. 2001). 5-HT plays important roles in the central nervous system (CNS) with 
respect to the regulation of a variety of functions including sleep (Markov and Goldman 2006) 
and pain (Butkevich et al. 2005). The number of different physiological roles for 5-HT can be 
explained based on its wide localization in the CNS and the variety of its receptor subtypes and 
isoforms (5-HT1 to 5-HT7 receptors, many having multiple isoforms) (Hoyer et al. 2002).  
Because 5-HT is one of the most important neurotransmitters in the mammalian CNS, its 
dysregulation is associated with a number of mental health diseases such as schizophrenia and 
depression. Serotonin is produced by neurons in the raphe nuclei and secreted from serotonergic 
nerve terminals. Serotonin receptors play an important role in brain development, and 5-HT 
signaling affects synaptic plasticity and neurogenesis in both the developing and adult brain. All 
seven subtypes of 5-HT receptors are expressed in the CNS (Meltzer et al. 2003; Millan 2006; 
Raymond et al. 2001; Bockaert et al. 2006). The 5-HT receptor subfamilies overlap with respect 
to their pharmacological properties, amino acid sequences, and the second messenger signaling 
pathways they initiate (Hoyer et al. 1994). Most 5-HT receptors are GPCRs, with the exception of 
5-HT3, which is an ionotropic receptor (Martinowich and Lu 2008). 5HT1 and 5HT5 receptors 
are Gαi/o-coupled receptors that typically inhibit adenylate cyclase (AC); 5HT4, 6, and 7 receptors 
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are Gαs-coupled receptors that typically stimulate AC. Activation of AC leads to the elevation of 
cAMP production, resulting in protein kinase A (PKA) activation. Phospholipase C (PLC) β is 
activated by a Gαq-coupled 5-HT2 receptor whereas the 5-HT3 receptor is a ligand-gated ion 
channel (Millan et al. 2008). PLC activation results in the accumulation of phosphatidylinositol 
4,5-bisphosphate (PIP2) to produce IP3 and diacyl-glycerol (DAG). Generation of IP3 increases 
intracellular Ca2+ levels and DAG activates Ca2+ and phospholipid-dependent protein kinase 
(PKC) (Raymond et al. 2001). 
1.1.1  5-HT7 receptor function 
The most recently discovered 5-HT receptor is the 5-HT type 7 receptor. At the time of its 
discovery in 1993, selective ligands had not yet been developed (Hedlund 2009). After the 
discovery of selective agonists such as AS-19 (Meltzer et al. 2011), it became possible to 
investigate the function and localization of 5-HT7 receptors (Ikeda et al. 2006; Thomas and 
Hagan 2004). 
5-HT affects a variety of membrane-bound receptors, and its receptors are expressed in both the 
central and peripheral nervous system as well as in non-neuronal tissue. 5-HT7 receptors are 
expressed in smooth muscle and promote relaxation within the vasculature in the gastrointestinal 
tract. The highest 5-HT7 receptor densities are found in both neurons and support cells in the 
thalamus, the hypothalamus, the suprachiasmatic nucleus, the prefrontal cortex, the hippocampus, 
and the amygdala (Mahe et al. 2004b; Thomas and Hagan 2004). Based on its initial 
identification in the suprachiasmatic nucleus, one of the first roles proposed for 5-HT7 was the 
regulation of sleep/wake cycles (Lovenberg et al. 1993).  
5-HT7 receptors are Gαs-coupled receptors; their activation leads to an increase both in adenylyl 
cyclase activity and in the intracellular level of cAMP, a second messenger. Activation of the 5-
HT7 receptor also increased intracellular Ca2+-stimulated AC in the rat cerebral cortex and 
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hippocampus (Mons et al. 1998; Mork and Geisler 1990), and this effect was independent of PKC 
(Baker et al. 1998). The 5-HT7 receptors endogenously expressed by cultured hippocampal 
neurons in rat also stimulated MAP kinase (ERK1/2), and this effect was not sensitive to pertussis 
toxin, indicating that Gαi/o-proteins are not involved in this pathway (Errico et al. 2001).  
 
Table 1.1 5-HT receptor subtypes and the CNS 
	  
Seven 5-HT receptor subtypes are expressed in the CNS, each with its own unique signaling and 
functional properties. Activation of GPCRs stimulates intracellular second messenger cascades. 
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1.1.2 5-HT7 receptor variants 
In humans, the serotonin receptor encoded by the HTR7 gene is located on chromosome 10 
(10q21-q24) (Gelernter et al. 1995) and possesses three exons separated by two introns (found in 
the second internal loop and in the intracellular carboxyl terminal) (Heidmann et al. 1997; Shen et 
al. 1993; Ruat et al. 1993), which are transcribed into three different splice variants (Raymond et 
al. 2001; Heidmann et al. 1997). Four major 5-HT7 receptor splice variants have been identified 
in mammals (5-HT7a-d) (Heidmann et al. 1997; Jasper et al. 1997; Stam et al. 1997), of which 
humans express three: 5-HT7a/b/d (Heidmann et al. 1997). In humans, the 5-HT7a and 5-HT7b 
receptors are in the major isoforms (Heidmann et al. 1997). The 5-HT7a is a full-length receptor 
(445 aa), while 5-HT7b contains 432 aa, which is truncated by 13 aa because of the introduction 
of an in-frame stop codon. The 5-HT7c and 5-HT7d receptors contain 479 aa due to the retention 
of an extra exon (exon C in rat and exon D in humans, which are located in the second intron) 
that results in a longer carboxyl terminal end (35 aa in rat and 47 aa in human) (Krobert and Levy 
2002; Heidmann et al. 1997; De Martelaere et al. 2007). Although the level of expression differs 
between isoforms, no significant functional differences, such as signal transduction and 
distribution, have yet been observed (Krobert et al. 2001).  
PDZ proteins interact with the C terminal end of GPCRs and contribute to the signal transduction 
properties and trafficking of GPCRs (Chetty et al. 2009).Notably, the 5-HT7a and 5-HT7d 
receptors do not contain PDZ motifs, whereas 5-HT7b and 5-HT7c receptors do contain PDZ 
motifs (Heidmann et al. 1998). The PDZ domain contains approximately 90 aa and helps to 
anchor transmembrane proteins to the cytoskeleton and hold together signaling complexes 
(Ranganathan and Ross 1997).  
5-HT7 receptors displayed inverse agonist responses when treated with a number of antagonists 
(Romero et al. 2006), and they were rapidly desensitized in recombinant systems by both agonists 
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and antagonists (Krobert et al. 2006). As measured by 5-HT-stimulated cAMP accumulation in 5-
HT7 receptor-expressing cells, several antipsychotic agents with affinities for the 5-HT7 receptor, 
including respiridone, appeared to “inactivate” 5-HT7 receptors after brief exposure to these 
agents (Toohey et al. 2009; Vasefi et al. 2012). Toohey et al. (2009) hypothesized that these 
neuroleptics induced a stable 5-HT7 conformation that prevents the receptor activation of Gαs. 
Although 5-HT7 receptors have been identified as Gαs-coupled in HEK293 and NIH3T3 cells, 
there is some evidence that 5-HT7 receptors may also couple to Gα12 (Kvachnina et al. 2005). 
The pharmacology of 5-HT7 receptors involves several unique aspects, including very high basal 
activity and rapid desensitization and downregulation by agonists. Additionally, 5-HT7 receptors 
can be inactivated by antagonists, including therapeutically useful antipsychotic medications 
(Krobert and Levy 2002; Mahe et al. 2004b). Serotonin receptors interact with several other 
signaling systems in the CNS, including the excitatory neurotransmitter glutamate. Clinical data, 
animal studies, electrophysiological data, and biochemical data have revealed several points of 
crosstalk between 5-HT receptors and glutamate pathways. 
1.1.3 Schizophrenia 
1.1.3.1 Definition 
Schizophrenia is a chronic and severe brain disorder that affects about 1 % of the population 
worldwide (Huang et al. 2012). Its symptoms can be divided into three categories: (A) positive 
symptoms that are not normally observed in patients, such as hallucinations; (B) symptoms 
involving loss of normal functioning, such as emotional flattening; (C) cognitive symptoms, such 
as disordered thinking (Kay et al. 1987; Huang et al. 2012). 
Several neuroimaging techniques have revealed that schizophrenia is characterized by abnormal 
brain structure and atypical responses to cognitive tasks (Vita et al. 2006; Glahn et al. 2008; 
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Ellison-Wright and Bullmore 2009). Schizophrenia is described as a neurodegenerative disease 
that derives from neurodevelopmental deficits. Evidence suggests a disturbance of glutamatergic 
neurotransmission and especially NMDA receptor-mediated signaling in schizophrenia patients 
(Fatemi and Folsom 2009; Belforte et al. 2010). The psychotomimetic agents ketamine and 
phencyclidine (PCP) induce symptoms of schizophrenia by blocking NMDA receptor activity 
(Javitt and Zukin 1991; Goff and Coyle 2001; Arguello and Gogos 2006), and NMDA receptor 
antagonists induce schizophrenic behaviour in rodents (Goff and Coyle 2001; Arguello and 
Gogos 2006; Gainetdinov et al. 2001). Genetic and pharmacological studies show that 
glutamatergic dysfunction, especially with the involvement of NMDA receptors, is a significant 
factor in the abnormalities seen in schizophrenia (Aida et al. 2012). Ketamine and PCP do not 
cause neurotoxic effects in rats until the rats reach puberty (Stone et al. 2007), possibly because 
neuronal connections involved in the neurotoxicity of NMDA receptor antagonists are not fully 
developed until late adolescence (Olney et al. 1999; Stone et al. 2007). This evidence supports 
the current view of schizophrenia as a disorder that likely begins in early development but does 
not manifest until late adolescence or early adulthood (Murray and Lewis 1987; Stone et al. 
2007). Glutamate levels are notably higher in the cortex of schizophrenic patients (Olbrich et al. 
2008).  Goto et al. (2012) reported that treatment with atypical antipsychotic drugs reduces 
glutamate levels in early-stage schizophrenia (Goto et al. 2012).  The levels of cortical glutamate 
released and the expression of NMDA receptors would be expected to change depending on the 
stage of the illness (Stone et al. 2007).  
1.1.3.2 Risk factors 
One of the strongest factors contributing to the development of schizophrenia is genetics (Owen 
et al. 2005). Molecular genetic studies of schizophrenic patients indicated that specific genes may 
increase the risk of developing the disease (Harrison and Owen 2003). Other researchers 
suggested that deletions or duplication of DNA sequences within genes is linked to schizophrenia 
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(Walsh et al. 2008; Xu et al. 2008). However, fetal environmental factors, such as maternal 
infection and stress (Brown 2006), as well as childhood environmental factors may also affect the 
incidence of schizophrenia (McGrath et al. 2008; March et al. 2008). 
1.1.3.3 Treatment 
Antipsychotic drugs that block D2-class dopamine receptors are the primary treatment for 
schizophrenia (Kapur and Mamo 2003). They are categorized as two classes: typical and atypical 
(van Os and Kapur 2009). Typical antipsychotics such as chlorpromazine, also called first-
generation antipsychotics, block D2-receptors with very high affinity (Seeman 2006). Typical 
antipsychotics reduce positive symptoms of schizophrenia such as delusions but also cause 
several adverse effects such as pseudo-Parkinsonism. Atypical antipsychotics, known as second-
generation antipsychotics, such as risperidone, are effective for treating both positive and 
negative symptoms and result in fewer side effects than do typical antipsychotics (Widschwendter 
and Fleischhacker 2005; van Os and Kapur 2009). Despite the benefits of atypical over typical 
antipsychotics, the successful treatment of schizophrenia remains poor. Improving and increasing 
the efficacy of this type of treatment with fewer side effects requires the discovery of additional 
methods of intervening in the pathology of the disease. 
1.1.4  Depression 
1.1.4.1  Definition 
Depression affects one in six individuals during their lifetime and has an impact on a person’s 
thoughts, emotions, and behaviour (Kessler et al. 2005). Diagnostic criteria include a depressed 
mood for longer than 6 months, abnormal appetite, abnormal sleep patterns, and suicidal 
thoughts.   
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1.1.4.2 Risk factors 
For depression related to life events, risk factors include job problems and relationship issues. 
Non-psychiatric illnesses such as chronic pain and medical therapies such as high blood pressure 
treatment can cause a depressed mood in a significant number of patients (Saravane et al. 2009 ; 
Shaffery et al. 2003). Investigating the pathophysiology of depression is a challenge because 
symptoms of depression such as guilt and suicidal thoughts are impossible to reproduce in animal 
models (Krishnan and Nestler 2008). However, there are animal behavioural tests and 
pharmacological studies that can help with the study of depression. Anatomically, the limbic 
system is involved in depression, and therapy may exert an influence on that system (Berton and 
Nestler, 2006). Clinical studies have shown that activity in the prefrontal cortex and amygdala is 
increased in depressed patients and also in healthy volunteers who are experiencing sadness 
(Drevets 2001; Ressler and Mayberg 2007). The volume of post-mortem gray matter and the 
number of cells in the prefrontal cortex are also decreased (Sheline 2003). 
1.1.4.3  Treatment 
The primary targets of currently available antidepressant drugs are the monoamine system 
(Berton and Nestler 2006). Tricyclic antidepressants (TCAs) such as desipramine are used to treat 
depression. TCAs inhibit 5-HT and/or norepinephrine (NE) and/or dopamine (DA) reuptake by 
blocking the transport of the neurotransmitter in order to increase their synaptic concentration 
(Elhwuegi 2004; Holtzheimer and Nemeroff 2006). Monoamine oxidase inhibitors such as 
phenelzine inhibit monoamine oxidase and keep 5-HT and NE levels elevated by preventing their 
metabolism (Youdim et al. 2006). Selective serotonin reuptake inhibitors (SSRIs) such as 
citalopram target 5-HT transporters in order to prevent serotonin uptake from the synaptic area 
(Holtzheimer and Nemeroff 2006).  
	  	   	  10 
1.1.5  5-HT7 receptors in CNS disease 
5-HT7 receptors are implicated in numerous CNS functions, such as cognition (Cifariello et al. 
2008), learning and memory (Perez-Garcia and Meneses 2005; Liy-Salmeron and Meneses 2007), 
and sleep (Thomas et al. 2003), as well as in specific disease states, including migraine headaches 
(Agosti 2007),  epilepsy (Witkin et al. 2007), and anxiety (Wesolowska et al. 2006b). The 
extensive distribution of 5-HT7 receptors in selected brain areas suggests that they are important 
in learning and memory.  
Because of the high affinity of 5-HT7 receptors for several atypical antipsychotics such as 
clozapine and resperidone as well as for antidepressants such as citalopram, it has been suggested 
that the 5-HT7 receptor might play a role in mental health diseases and their treatment (Hedlund 
2009). Genetic associations between 5-HT7 genes and schizophrenia have also been reported 
(Ikeda et al. 2006). The relationship between 5-HT7 receptors and mental health has provided an 
incentive for the investigation of 5-HT7 receptor receptors as pharmaceutical therapies (Mullins 
et al. 1999; Sleight et al. 1995). 
Traditional neuroleptic drugs have been predominantly D2-class dopamine receptor antagonists 
(Seeman et al. 1987). However, many neuroleptics antagonize several other classes of GPCRs, 
such as the 5-HT7 receptor (Hedlund 2009). In schizophrenics, 5-HT7 receptor mRNA levels are 
downregulated in the dorsolateral prefrontal cortex but not in the hippocampus (Hedlund 2009). 
The 5-HT7 receptor antagonist SB 656104 (Uzun et al. 2005; Galici et al. 2008) inhibits a 
number of drug-induced psychosis models (Galici et al. 2008) while clozapine, an atypical 
neuroleptic, regulates 5-HT7 receptor expression in HeLa cells (Zhukovskaya and Neumaier 
2000). The pharmacological blockade of 5-HT7 receptors or the deletion of the 5-HT7 receptor 
gene also leads to antidepressant-like behavioural effects, such as reduced immobility in both a 
forced swimming test and a tail suspension test in mice (Hedlund 2009; Bonaventure et al. 2007; 
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Wesolowska et al. 2006b; Wesolowska et al. 2006a). The levels of 5-HT7 receptor mRNA were 
increased in rat hippocampus after acute stress (Yau et al. 2001). Several antidepressants also 
have an affinity for 5-HT7 receptors (Lucchelli et al. 2000; Hedlund 2009), including 
amisulpiride (Abbas et al. 2009). 
 
In addition to possible antipsychotic and antidepressant actions, the selective 5-HT7 receptor 
antagonist SB 269970 induced an anxiolytic effect in rats and mice (Hagan et al. 2000). 5-HT7 
receptor antagonists may also reduce pain transmission as SB 269970 increased the number of 
shocks tolerated by the animal in the Vogel test as well as the number of entries onto open arms 
and the amount of time spent in those arms but did not produce these effects in knockout mice 
(Hedlund 2009). Although both pharmacological and genetic studies of animal models support a 
role for 5-HT7 receptor signaling as a possible avenue for the treatment of mental health diseases, 
the exact role of 5-HT7 receptor signaling in CNS dysfunction is unknown (Hedlund 2009). 
Further research will aid in an understanding of the impact of the 5-HT7 receptor signaling on 
cognitive function and help to elucidate possibly uses for treating specific cognitive disorders. 
1.2  PDGF receptors 
Platelet-derived growth factor (PDGF) initially purified from human platelets (Heldin and 
Westermark 1999) binds to PDGF receptors (PDGFRs) that are receptor tyrosine kinases (RTKs) 
and plays a key role in the regulation of cell proliferation, differentiation, and survival (Blume-
Jensen and Hunter 2001). RTK activation occurs through growth factor binding and the 
dimerization of the receptor (Ullrich and Schlessinger 1990; Lemmon and Schlessinger 2010). 
The binding of growth factors in the extracellular domain of the RTK brings the two receptors 
into close proximity, stimulates tyrosine kinase activity, and results in multiple phosphorylated 
tyrosine residues that facilitate several downstream signaling pathways (Clayton et al. 2005). 
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1.2.1  PDGF receptor expression and function 
PDGF exists as dimers of four polypeptides: PDGF-A, -B, -C, and -D. These either homo-
dimerize or hetero-dimerize into PDGF-AB, -AA, -BB, -CC, and -DD. The PDGF isoforms act 
through PDGF α and β receptors (Fredriksson et al. 2004). The molecular sizes of α and β 
receptors are 170 kDa and 180 kDa, respectively (Heldin and Westermark 1999). The α-receptor 
binds to either A- or B-chains of PDGF whereas the β-receptor binds to B-chains with high 
affinity. PDGF receptors are widely expressed throughout the CNS (Valenzuela et al. 1997). 
PDGFβ receptors are found almost exclusively in pyramidal neurons in the hippocampus (Smits 
et al. 1991; Beazely et al. 2009) whereas the PDGFα receptor and its primary ligand, PDGF-AA, 
are found in non-neuronal cells (Yeh et al. 1993; Fruttiger et al. 1996; Woodruff et al. 2004). 
Both PDGFα and PDGFβ are expressed in the hippocampus (Heldin et al. 1998).  
After PDGF binding to their receptors, the tyrosine kinase domains transphosphorylate one 
another on multiple tyrosine residues. Effectors such as phospholipase C (PLC) γ, 
phosphatidylinositol 3-kinase (PI3-kinase), Src family tyrosine kinases, tyrosine phosphatases 
such as SHP-2, and a GTPase-activating protein (GAP) for Ras are activated by the 
phosphorylation of the PDGF receptor (Heldin 1992; Heldin and Westermark 1999). Grb2/Sos 
adaptor proteins become activated after binding directly to the PDGF receptor or indirectly 
through Shc protein. Grb2/Sos converts inactive Ras-GDP to active Ras-GTP. Upon RTK 
phosphorylation, Shc binds to the Grb2/Sos complex and activates the Ras-MAPK signaling 
pathway. Activation of Ras is an important factor in several cellular responses (Heldin and 
Westermark 1999). Distinct signal transduction pathways may thus be initiated through each SH2 
domain-containing proteins activated by PDGF receptor binding (Heldin and Westermark 1999). 
Stat family molecules also bind to the activated PDGF receptor and become phosphorylated 
(Heldin and Westermark 1999). The Stat family of transcription factors can affect the 
transcription of specific genes after tyrosine phosphorylation (Heldin et al. 1998). Thus, by direct 
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activation of effector proteins or via cytoplasmic adaptor proteins, RTKs initiate a wide variety of 
downstream signaling pathways. 
1.2.2 PDGF receptors and neuroprotection 
The PDGFβ receptor is involved in neuroprotection against ischemic events (Egawa-Tsuzuki et 
al. 2004). Rapid increases in PDGF-B chain mRNA transcripts have been reported after rat brain 
focal ischemia (Ohno et al. 1999). The expression of PDGF-A and -B mRNA and PDGF-BB and 
-AB dimers has been reported to increase in neurons and support cells surrounding areas damaged 
during ischemia (Krupinski et al. 1997). In addition to the upregulation of PDGFβ receptors and 
PDGF-B chain expression after ischemic events, exogenously applied PDGF-BB is also 
neuroprotective with respect to focal ischemia (Sakata et al. 1998) and glutamate- and NMDA-
induced cell death in hippocampal neurons (Egawa-Tsuzuki et al. 2004; Tseng and Dichter 2005).  
The neuroprotective effect of PDGF involves the inhibition of N-methyl-D-aspartate (NMDA) 
receptors, specifically the NMDA receptors containing NR2B subunits (Beazely et al. 2009). 
Interestingly, dopamine receptor activation in either the hippocampus or prefrontal cortex 
increases the PDGFβ receptor activity and results in an inhibition of NMDA currents, suggesting 
a relationship between dopaminergic hyperactivity and NMDA receptor hypoactivity (Valenzuela 
et al. 1996; Lei et al. 1999; Beazely et al. 2009; Kotecha et al. 2002). An understanding of the 
role of neuronal PDGF signaling can therefore help explain the neurodevelopment impairment 
associated with schizophrenia (Carter 2006). 
With respect to depression, NMDA receptors may be an essential component of the pathogenesis 
and treatment (Petrie et al. 2000; Hashimoto 2010). A number of studies have reported increased 
spinal fluid and plasma glutamate levels in patients with major depressive disorders (Kim et al. 
1982; Altamura et al. 1993). Many therapeutically useful antidepressant medications decrease 
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NMDA receptor activity, and NMDA receptor antagonists exhibit antidepressant activity (Petrie 
et al. 2000; Hashimoto 2009). Focusing on specific NMDA receptor subunit antagonists as 
potential antidepressants is an interesting possibility. The specific NR2B-subunit antagonist Ro 
25-6981 acts as an antidepressant in rodents (Maeng et al. 2008), and the antagonist CP-101,606 
shows promising results in treatment-resistant depressed patients (Preskorn et al. 2008). It 
remains unclear whether and how PDGF signaling may be involved in the regulation of NMDA 
receptor activity in the context of mental illness. 
1.2.2 GPCR regulation of PDGF receptor expression and activity 
Serotonin is involved in the regulation of multiple cellular functions (Wilkinson et al. 1991), 
including the promotion of cell growth (Martinowich and Lu 2008). Growth factor receptors can 
be activated when a specific ligand interacts with the binding site on the receptor (Saito et al. 
2001). As described above, the binding of the PDGF to the receptor leads to dimerization and 
phosphorylation in the receptor and triggers numerous signaling pathway and cell responses. 
However, it has been reported that a ligand-binding domain is not a requirement for receptor 
dimerization (Kwatra et al. 1992). This finding suggests that dimerization and 
autophosphorylation of the growth factor receptor may occur in a ligand-independent manner. 
Several studies have also demonstrated that GPCR agonists, such as angiotensin II, endothelin-1, 
and thrombin, stimulate RTK activity even in the absence of an exogenous growth factor 
(Wetzker and Bohmer 2003; Lowes et al. 2002; Saito et al. 2001). Nebigil et al. (2000) 
demonstrated that, in the absence of the ligand, activation of the 5-HT2B Gαq-coupled receptor 
triggers the phosphorylation of the PDGFβ receptor (Nebigil et al. 2000). This effect involved the 
activation of c-Src kinase by 5-HT to stimulate the phosphorylation and activation of the PDGF 
receptor (Nebigil et al. 2000). Liu et al. (2007) reported that 5-HT leads to the 
autophosphorylation of the PDGFβ receptor by activating 5-HT transporters in smooth muscle 
cells of the pulmonary artery (Liu et al. 2007a).  
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5-carboxamidotryptamine (5-CT) activates Gαi/o-coupled receptors, such as 5-HT1 and 5-HT5 
receptors, and Gαs-coupled receptors, such as 5-HT7 receptors (Eglen et al. 1997; Hoyer and 
Martin 1997). Kruk et al. (2013) recently showed that 5-CT transactivates PDGFβ receptors in 
neuronal cell cultures (Kruk et al. 2013b). Numerous studies have shown that the transactivation 
of RTKs for a number of GPCRs occurs through exclusively intracellular signaling pathways 
(Daub et al. 1996). An example of such a pathway is the D2-class dopamine receptor 
transactivation of PDGF receptors in hippocampal neurons (Kotecha et al. 2002). The 
transactivation of RTK receptors by GPCR initiation may regulate a population of RTKs that 
differ from those activated by direct ligand binding (Heeneman et al. 2000).  
1.3 Glutamate receptors 
Metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors (iGluRs) are the 
two major types of glutamate receptors. mGluRs are coupled to G-proteins, and their action is 
mediated by second-messenger systems. iGluRs are ligand-gated ion channels of three types: 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate, and NMDA receptors. 
All are involved in excitatory neurotransmission (Dingledine et al. 1999). 
1.3.1  NMDA receptor subunits 
NMDA receptors are composed of two compulsory NR1 subunits and at least two additional 
subunits of the following types: NR2A, NR2B, NR2C, NR2D, and NR3 (Paoletti and Neyton 
2007). The properties of an NMDA receptor are dependent on its subunit composition 
(Dingledine et al. 1999). For example, NR1 plays a central role in NMDA receptor trafficking at 
the synapse and is essential for surface expression (Nong et al. 2003; Perez-Otano et al. 2001). 
Extracellular ligand-binding sites for glutamate are located in the NR2 subunits (Laube et al. 
1997). The dominant NR2 forms in the hippocampus are NR2A and NR2B (Groc et al. 2006; Al-
Hallaq et al. 2007). NMDA receptors are constitutively blocked by extracellular Mg2+ ions and 
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open only upon depolarization and agonist binding (Mayer et al. 1984; Nowak et al. 1984). The 
binding of glutamate as the agonist and glycine as the co-agonist is necessary for channel opening 
(Laube et al. 1997). However, the binding of glycine alone induces internalization of the NMDA 
receptor (Nong et al. 2003). AMPA, kainate, and NMDA receptors are permeable to Na+ (influx) 
and K+ (outflux) ions, but only the NMDA receptor is permeable to Ca2+ (Arundine and 
Tymianski 2003). NR1/NR2A and NR1/NR2B channels have a stronger voltage dependence on 
Mg2+ ions than do NR1/NR2C and NR1/NR2D (Monyer et al. 1994). NMDA receptor activity 
and trafficking are regulated by several protein kinases, including protein kinase A (PKA), 
protein kinase C (PKC), Ca2+-calmodulin-dependent protein kinase II (CaMKII), cyclin-
dependent kinase 5 (CDK5), and members of the Src families of tyrosine kinases (Wang et al. 
2006). NMDA receptor responses are also regulated by Zn2+ ions, nitric oxide, polyamines, 
steroids, and protons (Waxman and Lynch 2005). 
1.3.2  NMDA receptors and excitotoxicity  
Calcium influx through NMDA receptors plays a critical role in synaptic plasticity, a cellular 
mechanism involved in learning and memory. However, excessive calcium influx is detrimental 
to neurons. Excitotoxicity is caused by the excessive release of glutamate from presynaptic 
terminals and/or by the inhibition of reuptake systems (Chen and Wyllie 2006). The 
overactivation of NMDA receptors results in an excessive influx of Ca2+ ions (Choi et al. 1987). 
Most extrasynaptic NMDA receptors contain the NR2B subunit and synaptic NMDA receptors 
are primarily NR2A-containing receptors (Groc et al. 2006; Tovar and Westbrook 2002; Groc et 
al. 2007). Extrasynaptic NR2B-containing NMDA receptors directly cause excitotoxic cell death 
through an influx of Ca2+ (Hardingham and Bading 2002; Zhang et al. 2007), and synaptic 
NR2A-containing receptors, despite also increasing Ca2+ levels, provide neuroprotection during 
ischemia (Liu et al. 2007b; von Engelhardt et al. 2007). The involvement of glutamate 
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excitotoxicity has been suggested with respect to numerous brain disorders, including stroke and 
Alzheimer’s disease, but the exact mechanism(s) remain unclear. 
1.3.3  Mental health diseases related to NMDA receptors 
The NMDA receptor has been implicated in multiple neuronal functions, ranging from synapse 
plasticity to learning and memory (Dingledine et al. 1999). Glutamate is very important for the 
physiological balance of the CNS and dysfunctional NMDA receptors are strongly linked to the 
pathophysiology of mental disorders (Tsai et al. 2002).  
In schizophrenia, it is the hypofunction of glutamatergic systems that is associated with 
schizophrenia symptoms (Carlsson and Carlsson 1990; Toru et al. 1994). In the brains of 
schizophrenic patients, the K+-dependent release of glutamate is decreased (Sherman et al. 1991), 
and the number of glycine binding sites is increased (Ishimaru et al. 1994). Interestingly, D-
cycloserine, a partial agonist at the glycine binding site, increases symptoms, and this effect is 
reduced by the antagonistic properties of this agent (Cascella et al. 1994).  
Researchers have recently determined that ketamine (a non-competitive NMDA receptor 
antagonist) produced an antidepressant effect in animal models (Maeng et al. 2008). Such 
findings suggest that reducing glutamatergic activity in the brain can improve depressive 
symptoms (Krishnan and Nestler 2008). An examination of postmortem depressed individuals 
revealed a decreased allosteric coupling of the glycine site to NMDA receptors (Nowak and 
Wender 1994). Taken together, these data suggest that NMDA receptor antagonists have an 
antidepressive-like effects in animal models and in humans (Trullas and Skolnick 1990; Moryl et 
al. 1993).  
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1.3.4  NMDA receptor and serotonin  
Serotonin (5-HT) is a major monoamine neurotransmitter in the mammalian central nervous 
system (CNS). Multiple physiological, therapeutic, and pathological pathways are dependent on 
serotonergic signaling. The serotonergic system in the prefrontal cortex (PFC) is involved in the 
control of emotion and cognition under both normal and pathological conditions (Buhot 1997; 
Davidson et al. 2000). At least 15 different 5-HT receptor isoforms are expressed in humans 
(O'Neil and Emeson 2012). 5-HT regulates neuronal growth, survival, and maturation (Lotto et 
al. 1999; Whitaker-Azmitia et al. 1996) and also influences the neuronal activity of the 
glutamatergic system in adults (Hoyer 2002; Verge and Calas 2000).  
1.3.5 NMDA and 5-HT7 receptors 
5-HT7 receptors are highly expressed in the suprachiasmatic nucleus (Thomas and Hagan 2004) 
but have also been identified in both neurons and support cells in the prefrontal cortex, the 
hippocampus, the thalamus, the hypothalamus, and the amygdala (Mahe et al. 2004b; Thomas 
and Hagan 2004). The regulation of sleep/wake cycles was one of first roles proposed for 5-HT7 
(Lovenberg et al. 1993). 5-HT7 receptors have four isoforms (A, B, C, and D), which exhibit no 
differences in their respective pharmacology, signal transduction, or tissue distribution 
(Heidmann et al. 1997; Jasper et al. 1997). 5-HT7 receptors mediate 5-CT-induced hypothermia 
in guinea pigs (Marcos et al. 2009), with clear evidence of the receptor crosstalk that is common 
between 5-HT receptors and other receptors (Marcos et al. 2009). 
As mentioned above PDGFβ receptors inhibit NMDA receptors through the selective 
internalization of NR2B-containing NMDA receptors (Beazely et al. 2009), which are 
internalized after phosphorylation at the tyrosine 1452 site in the hippocampus. The inhibition of 
NMDA receptor currents by PDGFβ receptors is due to the activation of phospholipase Cγ 
(PLCγ), the release of intracellular calcium, and the stability of the actin cytoskeleton (Henke et 
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al. 1999) and also involves decrease in the surface expression of NR2B subunits of the NMDA 
receptor (Beazely et al. 2009).  
Conflicting evidence has been found with respect to the effects of 5-HT7 receptors on neuronal 
and synaptic activity. The decrease in the slow afterhyperpolarization (sAHP) caused by 5-HT7 
receptors leads to increased synaptic excitability in the hippocampus (Bacon and Beck 2000; 
Tokarski et al. 2005), possibly through the inhibition of calcium-dependent potassium channels 
(Gill et al. 2002). However, other reports have suggested that 5-HT7 receptors decreased 
glutamatergic signaling. The circadian phase advances in the dorsal raphe nucleus (DRN) involve 
an inhibition of glutamatergic neurotransmission (Duncan and Congleton 2010), and the 5-HT7 
receptors in the DRN antagonize the NMDA-receptor-dependent synaptic release of both 
serotonin and glutamate (Harsing et al. 2004). The glutamate-mediated increase in intracellular 
calcium was inhibited by the activation of 5-HT7 receptors in rat suprachiasmatic nuclei (SCN) 
(Smith et al. 2001), and the amplitude of glutamate excitatory postsynaptic potentials (EPSPs) 
decreased after the activation of 5-HT7 receptors in mouse SCN (Quintero and McMahon 1999). 
Recently, Kobe and coworkers demonstrated that the activation of 5-HT7 receptors increases the 
number of dendrites and promotes the formation of synapses in primary hippocampal cultures but 
does not affect the magnitude of the LTP (Kobe et al. 2012). However, in 5-HT7 receptor 
knockout mice, a reduced induction of LTP has been demonstrated (Roberts et al. 2004).  
The ability of 5-HT7 receptors to regulate the expression of PDGF receptors, as discussed in the 
results section, may help explain the apparent lack of clarity associated with the effects of 5-HT7 
receptors on glutamatergic signaling. It should be noted that in some of the studies cited above, 5-
HT7 receptor agonists were applied for 5 min to 10 min (Harsing et al. 2004; Quintero and 
McMahon 1999) whereas in others, animals/tissues were treated for hours to days (Kobe et al. 
2012). Furthermore, in none of the studies cited above were selective 5-HT7 agonists used, and 
only Kobe et al. (2012) used a selective 5-HT7 receptor antagonist in their research.  
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NMDA receptors are tetrameric channels in the hippocampus with NR2A and NR2B being the 
dominant NR2 forms (Al-Hallaq et al. 2007). Studies have shown that antagonists of NMDA and 
5-HT7 receptors produce an effective treatment for both schizophrenia and depression. It is 
unclear how the antagonists of NMDA and 5-HT7 receptors affect signaling mechanisms. With 
respect to behavioural models, there are interactions between 5-HT, 5-HT receptors, and NMDA 
receptors. Little is known about 5-HT receptor subtypes, which regulate NMDA receptor activity. 
5-HT1A receptors have been found to inhibit NMDA receptor currents (Yuen et al. 2005) while 
5-HT3 receptor activation in cortical slices has been shown to reduce NMDA currents (Liang et 
al. 1998). Low concentrations of 5-HT2A/2C agonists also increased NMDA currents in a PKC-
dependent manner in prefrontal cortical slices (Arvanov et al. 1999). A number of questions 
remain unanswered, including how 5-HT7 receptors regulate NMDA receptor activity; whether 5-
HT7 and other 5-HT receptors target a specific subgroup of NMDA receptors (i.e., NR2A- or 
NR2B-containing NMDA receptors) and if so, what mechanism(s) are involved. 





Figure 1.1 Schematic displaying the proposed model by 5-HT7 receptor agonists 
indicating 5-HT7 receptor has potential for both positive and negative regulation 
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Chapter 2 
Acute 5-HT7 receptor activation increases NMDA-evoked current 
and differentially alters NMDA receptor subunit phosphorylation 
in hippocampal neurons  
2.1 Summary 
N-methyl-D-aspartate (NMDA) receptors are regulated by several G-protein coupled receptors 
(GPCRs) as well as receptor tyrosine kinases. Serotonin (5-HT) type 7 receptors are expressed 
throughout the brain including the thalamus and hippocampus. Long-term (2-24 h) activation of 
5-HT7 receptors promotes the expression of neuroprotective growth factor receptors, including 
the platelet-derived growth factor (PDGF) β receptors, which can protect neurons against 
NMDA-induced neurotoxicity. 
Acute (5 min) treatment of isolated hippocampal neurons with the 5-HT7 receptor agonist 5-
carboxamidotryptamine (5-CT) enhances NMDA-evoked peak currents and this increase in peak 
currents is blocked by the 5-HT7 receptor antagonist, SB 269970. In hippocampal slices, acute 5-
HT7 receptor activation increases NR1 NMDA receptor subunit phosphorylation and 
differentially alters the phosphorylation state of the NR2B and NR2A subunits. NMDA receptor 
subunit cell surface expression is also differentially altered by 5-HT7 receptor agonists: NR2B 
cell surface expression is decreased whereas NR1 and NR2A surface expression are not 
significantly altered. 
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2.2 Introduction 
Several studies have examined the ability of serotonin (5-HT) receptors to modulate NMDA 
receptor activity. For example, in isolated cortical neurons, activation of 5-HT1A receptors 
inhibits NMDA receptor currents (Yuen et al. 2005) and 5-HT3 receptor activation reduces 
NMDA currents in cortical slices (Liang et al. 1998). In contrast, in Xenopus oocytes, 5-HT2 
receptor activation increases NMDA receptor currents (Blank et al. 1996) and in prefrontal 
cortical slices, 5-HT2A/2C agonists enhance NMDA-evoked responses (Arvanov et al. 1999). 
The effect of 5-HT7 receptor ligands on NMDA-evoked currents remains unknown, however 
recent studies provide clear evidence for the regulation of glutamatergic signaling by 5-HT7 
receptors. 5-HT7 receptors inhibit NMDA-induced neurotransmitter release in the dorsal Raphe 
nucleus (DRN) and the physiological role of 5-HT7 receptors in circadian rhythms is linked to an 
inhibition of glutamate-dependent events (Harsing et al. 2004). In the suprachiasmatic nucleus, 
glutamate excitatory postsynaptic potentials (EPSPs) and glutamate-induced intracellular calcium 
levels are both inhibited by 5-HT7 receptor activation (Quintero and McMahon 1999; Smith et al. 
2001). Taken together, these studies suggest that 5-HT7 receptor activation decreases NMDA 
and/or glutamate receptor signaling. In contrast, 5-HT7 receptor knock-out mice display a 
reduced induction of long-term potentiation (LTP), the magnitude of LTP, and hippocampus-
associated learning compared to wild-type (Roberts et al. 2004). Therefore although there is 
evidence that 5-HT7 receptors negatively regulate NMDA/glutamate signaling, deletion of 5-HT7 
receptors decreased the magnitude of NMDA receptor-dependent events such as LTP. 
We recently identified the 5-HT7 receptor as a regulator of platelet-derived growth factor (PDGF) 
β receptor expression and activity (see Chapter 3). Activation of PDGFβ receptors by PDGF-BB 
selectively inhibits NR2B-containing NMDA receptor currents and this may be a mechanism of 
PDGFβ receptor-mediated neuroprotection (Beazely et al. 2009). Intriguingly, 5-HT7 receptor-
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induced upregulation of PDGFβ receptor is also sufficient to protect neurons against NMDA-
induced excitotoxicity (Figure 4.9, see Chapter 4). Thus, we proposed that long-term activation of 
5-HT7 receptors initiates pathways that ultimately negatively regulate NMDA receptor signaling. 
To clarify the direct effects of 5-HT7 receptor activation on NMDA receptor signaling we 
examined the effects of 5-HT7 receptor agonists and antagonists on NMDA-evoked currents, 
NMDA receptor subunit phosphorylation, and NR subunit cell surface expression. In isolated 
hippocampal neurons, application of the 5-HT7 receptor agonist, 5-CT, resulted in a rapid, robust, 
and sustained increase in peak NMDA-evoked currents. 5-HT7 receptor agonist treatment also 
differentially altered NMDA receptor subunit phosphorylation and cell surface expression. These 
data, along with our other work, suggest a model for differential NMDA receptor regulation by 5-
HT7 receptors over the short- and long-term. 
2.3 Materials and Methods 
Reagents and antibodies – 5-CT and LP 12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-
yl)-1- piperazinehexanamide hydrochloride) were purchased from Sigma (St. Louis, MO, USA). 
The 5-HT7 receptor antagonists SB 258719 ((R)-3,N-Dimethyl-N-[1-methyl-3-(4-
methylpiperidin-1-yl)propyl]benzene sulfonamide) and SB 269970 (R-3-(2-(2-(4-
methylpiperidin-1-yl)ethyl)-pyrrolidine-1-sulfonyl)-phenol were purchased from Tocris 
(Ellisville, MO, USA). Antibodies used include anti-NR1, anti-phospho-896-NR1, anti-phospho-
897-NR1, anti-NR2A, anti-phospho-pan-NR2A, anti-NR2B, anti-phospho-1252-NR2B, anti-
phospho-1336-NR2B, and anti-phospho-1472-NR2B were purchased from Millipore (Billerica, 
MA). 
Cell isolation and whole-cell recording – CA1 neurons were isolated from hippocampal slices of 
postnatal day 14-21 Wistar rats as previously described (Wang and MacDonald 1995). The 
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extracellular solution (ECF) was composed of 140 mM NaCl, 1.3 mM CaCl2, 25 mM N-2-
hydroxyethylpiperazine-N’-ethanesulfonic acid (HEPES), 33 mM glucose, 5.4 mM KCl, and 0.5 
µM tetrodotoxin, and 0.5 µM glycine, with pH of 7.3-7.4 and osmolarity ranging from 320-330 
mOsm. Recordings were done at room temperature. The intracellular solution consisted of 11 
mM ethyleneglycol-bis-(α-amino-ethyl ether) N,N’-tetra-acetic acid (EGTA) as intracellular 
calcium chelating buffer, 10 mM HEPES, 2 mM MgCl2, 2 mM tetraethyl ammonium chloride 
(TEA-Cl) to block K+ channel, 1 mM CaCl2, 140 mM CsF, and 4 mM K2ATP. NMDA currents 
were evoked by rapid application of NMDA solution delivered from a multi-barreled fast 
perfusion system for 2 sec in every minute.  
Western blot – Hippocampal slices were prepared, treated with drugs for 5 min, and homogenized 
chilled lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 30 
mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 0.5% SDS, 
and 1% triton-X-100; supplemented with Halt Protease and Phosphatase Inhibitor (Thermo, 
Fisher, Markham, Ontario) prior to use. Lysates were centrifuged at 14,000 x g for 20 min at 4°C 
and the supernatant was collected. The supernatant was subjected to SDS-PAGE and proteins 
were transferred to nitrocellulose membranes, blocked with 5% non-fat dry milk in Tris-buffered 
saline and 0.1% Tween for 1 h at room temperature or overnight at 4°C, and incubated in primary 
antibodies for 1 h at room temperature or overnight at 4°C. Membranes were washed three times 
in Tris-buffered saline with 0.1% Tween-20, incubated with HRP-conjugated secondary 
antibodies for 1 h at room temperature, washed again, and bound antibodies were visualized by 
the enhanced chemiluminescence using the chemiluminescent substrate (Millipore, Etobicoke, 
Ontario).  Images of Western blots were taken on the Kodak 4000MM Pro Imaging Station, and 
densitometric analyses were performed using the Kodak Molecular Imaging software. 
Membranes were then stripped and reprobed with other antibodies. 
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Surface Biotinylation Assay – Hippocampal slices were incubated for 5 min with 5-HT7 receptor 
agonists and antagonists. Slices were washed in ice-cold ECF and incubated with 0.5 mg/ml 
Sulfo-NHS-LC-biotin for 30 min. The biotin reaction was quenched by washing with 10 mM 
glycine. Slices were washed twice more and homogenized in lysis buffer. Lysate protein 
concentrations were normalized and lysates were incubated with streptavidin beads overnight at 4 
°C (Sigma). Beads were washed three times in lysis buffer and boiled in loading buffer for 5 min 
before separation by SDS-PAGE. 
Statistical Analysis – Statistical analysis of the data was performed using the Prism® GraphPad 
program. For electrophysiology, graphs and sample tracings were made using the Origin® 
program. Significance level was set at α = 0.05. Data was analyzed by one-way ANOVA or 
Student’s t-test where appropriate. 
Animals – All animal experiments were performed in agreement with the guidelines of the 
policies on the Use of Animal at the University of Waterloo and the University of Western 
Ontario. 
2.4 Results 
Application of the 5-HT7 receptor agonist, 5-CT, to isolated hippocampal neurons for 5 min 
robustly increased NMDA-evoked peak currents (Vasefi et al. 2013b). This effect occurred 
within minutes after 5-CT application and the increase in peak NMDA-evoked currents was 
sustained even after 5-CT was washed out (minutes 10-30). In addition to 5-HT7, 5-CT also 
activates 5-HT1 and 5-HT5 receptors (Hoyer et al. 1994; Eglen et al. 1997). However, the 
increase in NMDA-evoked currents by 5-CT was completely blocked by the 5-HT7 receptor-
selective antagonist, SB 269970 (Vasefi et al. 2013b).  
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To determine if 5-HT7 receptor activation alters NMDA receptor subunit phosphorylation we 
incubated hippocampal slices with 50 nM 5-CT in the absence or presence of the 5-HT7 receptor 
antagonist, SB 258719 (Mahe et al. 2004b). 5-HT7 receptors are coupled to Gαs in several cell 
lines (Thomas et al. 1999a, Crider et al. 2003, Mahe et al. 2004a, Andressen et al. 2006, Romero 
et al. 2006) and the application of 5-CT to hippocampal slices robustly increased NR1 receptor 
phosphorylation at the PKA phosphorylation site, serine 896 (Table 2.1). 5-CT application also 
increased the phosphorylation of the NR1 subunit at PKC-site serine 897 (Table 2.1). The 
increase in the PKC-site serine 896 phosphorylation was blocked by the PKC inhibitor Go 6983 
(Figure 2. 1A) and the increase in the PKA-site serine 897 phosphorylation was blocked by the 
PKA inhibitor, H89 (Figure 2.1B). A 5 min application of 5-CT resulted in a sustained elevation 
of NMDA-evoked current for at least 20 min after washout (Vasefi et al. 2013b). To determine if 
the observed changes in NR1 subunit phosphorylation were similarly sustained we treated 
hippocampal slices with 5-CT for 5 min, washed the slices, and waited an additional 20 min 
before homogenizing the tissue in lysis buffer. The phosphorylation state of both serine 896 and 
897 remained significantly elevated above control for 20 min after treatment with 5-CT (Figure 
2.1C, D). As mentioned above, 5-CT will also activate 5-HT1 and 5-HT5 receptors (Eglen et al. 
1997; Hoyer et al. 1994).  To confirm that the observed changes in NMDA receptor subunit 
phosphorylation were indeed due to the activation of the 5-HT7 receptor we incubated acutely-
dissected hippocampal slices with the 5-HT7-selective agonist, LP 12 (Leopoldo et al. 2007) in 
the absence or presence of the 5-HT7 receptor antagonists, SB 269970 and SB 258719 (Thomas 
et al. 1999b). Similar to the PKA phosphorylation site, serine 897 was phosphorylated (Figure 
2.2A, C) and this increased phosphorylation was sustained for at least 20 min (Figure 2.1D). 
Interestingly, we observed an even more robust increase in the phosphorylation of the adjacent, 
PKC-phosphorylated serine 896 (Figure 2.2B, C). However, the magnitude of the increase in 
serine 896 compared to serine 897 may be due to the lower basal phosphorylation state at serine 
896. The increase in serine 896 phosphorylation was also observed for at least 20 min after LP 12 
	  	   	  28 
treatment (Figure 2.1C).  The increased phosphorylation by LP 12 at both sites was blocked by 
SB 258719 (Figure 2.2) (Mahe et al. 2004b).  
Table 2.1 5-CT treatment differently alters NMDA receptor subunit 
phosphorylation. 
Treatment (5 min) NMDA subunit/ 
phosphorylation site 5-CT 5-CT + SB SB 269970 
NR1/896, n = 8 2.07 ± 0.39** 0.91 ± 0.31 1.06 ± 0.28 
NR1/897, n = 8 1.51 ± 0.13** 1.00 ± 0.39 0.95 ± 0.11 
NR2A/total, n = 10 0.71 ± 0.07** 0.97 ± 0.37 0.86 ± 0.17 
NR2B/1472, n = 5 2.79 ± 0.37** 1.49 ± 0.61 2.86 ± 1.33 
NR2B/1252. N = 10 1.39 ± 0.49 1.50 ± 0.23 1.53 ± 0.31 
NR2B/1336, n = 7 1.25 ± 0.19 1.98 ± 0.31 2.36 ± 0.36** 
 
Hippocampal slices were treated with 50 nM 5-CT in the absence or presence of 1 µM SB 
269970 for 5 min. Changes in the phosphorylation state for each antibody were normalized to 
control (vehicle-treated slices) and to total NR subunit expression. For each experiment a β-actin 
antibody was used to confirm equal loading. Data presented are the average and standard error. * 
p < 0.5, ** p < 0.01, compared to vehicle. 	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Figure 2.1 5-CT treatment of hippocampal slices increases NR1 phosphorylation at serines 
896 and 897. 
A) Hippocampal slices were treated with 50 nM 5-CT in the absence or presence of 1 µM Go 
6983 (GO) for 5 min. Increases in the phosphorylation state at serine 896 were normalized to 
control (vehicle-treated slices) and to total NR1. Data represent the average and standard error of 
10 independent experiments. * p < 0.5 compared to vehicle, ANOVA analysis with Dunnett’s 
post-test. INSET: representative Western blots showing serine 896 phosphorylation and the β-
actin loading control. B) Hippocampal slices were treated with 50 nM 5-CT in the absence or 
presence of 10 µM H89 for 5 min. Data represent the average and standard error of 10 
independent experiments. * p < 0.5 compared to vehicle, ANOVA analysis with Dunnett’s post-
test. INSET: representative Western blots showing serine 897 phosphorylation and the β-actin 
loading control. C) Hippocampal slices were treated with 50 nM 5-CT or 300 nM LP 12 for 5 
min, the slices were washed and incubated in drug-free buffer for an additional 20 min before 
lysis. Data represent the average and standard error of 8 independent experiments. * p < 0.5 
compared to vehicle, ANOVA analysis with Dunnett’s post-test. INSET: representative Western 
blots showing serine 896 phosphorylation and the β-actin loading control. D) Slices were treated 
as in C. Data represent the average and standard error of 4 independent experiments. * p < 0.5 
compared to vehicle, ANOVA analysis with Dunnett’s post-test. INSET: representative Western 
blots showing serine 897 phosphorylation and the β-actin loading control. 	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Application of LP 12 also differentially affects NR2 subunit phosphorylation. While LP 12 
significantly reduced the phosphorylation state of the NR2A subunit (Figure 2.3A, B), LP 12 
increased NR2B phosphorylation at tyrosine 1472 (Figure 2.3C, D). However the 
phosphorylation of NR2B at other tyrosine residues, 1252 and 1336, remained unchanged, with 
LP 12 inducing a 0.97 ± 0.12 (n = 12) and 0.93 ± 0.11 (n = 10) fold change, respectively, 
compared to control. The effects of LP 12 on the phosphorylation of NR2A and NR2B-Y1472 
were both blocked by SB 258719 (Figure 2.3). 5CT treatment similarly enhanced NR2B-Y1472 
phosphorylation and decreased NR2A phosphorylation (Table 2.1). 
Several pathways regulate NMDA receptor subunit cell surface expression. To investigate the 
effects of 5-HT7 receptor agonist treatment on the surface expression of the NMDA receptors 
subunits, we treated hippocampal slices with LP 12 in the absence or presence of SB 258719 for 5 
min. In hippocampal slices LP 12 treatment did not significantly change the cell surface 
expression of NR1 (0.92 ± 0.13 vs. control) and NR2A (1.05 ± 0.13 vs. control), but NR2B cell 
surface expression was reduced by approximately 25% (Figure 2.4). 
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Figure 2.2 5-HT7 receptor activation increases NR1 subunit phosphorylation. 
A) Hippocampal slices were treated with 300 nM LP 12 in the absence or presence of 1 µM SB 
258719 for 5 min. Increases in the phosphorylation state at serine 897 were normalized to control 
(vehicle-treated slices) and to total NR1. Data represent the average and standard error of 9 
independent experiments. ** p < 0.01 LP 12 vs. vehicle, # p < 0.01 vs. LP 12 vs. LP 12 + SB 
258719, * p < 0.5 compared to vehicle, ANOVA analysis with Bonferroni’s post-test. B) 
Hippocampal slices were treated as in A and Western blots were performed using an anti-
phospho-serine 896 antibody. Data represent the average and standard error of 10 independent 
experiments. ** p < 0.01 LP 12 vs. vehicle, # p < 0.01 vs. LP 12 vs. LP 12 + SB 258719, 
ANOVA analysis with Bonferroni’s post-test. C) Representative Western blots showing serine 
896 and serine 897 phosphorylation, total NR1, and β-actin. 
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Figure 2.3 5-HT7 receptor activation differentially alters NR2 subunit 
phosphorylation. 
A) Hippocampal slices were treated with 300 nM LP 12 in the absence or presence of 1 µM SB 
258719 for 5 min. Decreases in the phosphorylation state of NR2A were normalized to control 
(vehicle-treated slices) and to total NR2A. Data represent the average and standard error of 7 
independent experiments. * p < 0.05 LP 12 vs. vehicle ANOVA analysis with Dunnett’s post-test. 
B) Representative Western blots using anti-phospho-pan-NR2A, NR2A, and β-actin. C) 
Hippocampal slices were treated as in A. Increases in the phosphorylation state of NR2B at 
tyrosine 1472 were normalized to control (vehicle-treated slices) and to total NR2B. Data 
represent the average and standard error of 6 independent experiments. * p < 0.05 LP 12 vs. 
vehicle ANOVA analysis with Dunnett’s post-test. D) Representative Western blots using anti-
phospho-Y1472-NR2B, NR2B, and β-actin. 
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Figure 2.4 LP 12 application results in the selective reduction of the surface 
expression of NR2B. 
A) CA1 hippocampal slices were treated with vehicle, 300 nM LP 12, or LP 12 + 1 µM SB 
258719 for 5 min. The slices were biotinylated and lysates were incubated overnight with 
streptavidin beads. Data represent the average and standard error of 6 independent experiments.  
* p < 0.05 LP 12 vs. vehicle ANOVA analysis with Dunnett’s post-test. B) Total lysates or 
biotinylated samples were blotted using antibodies against NR2B or β-actin. 
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2.5 Discussion 
5-HT7 receptor knock-out mice have a reduced induction of LTP (Roberts et al. 2004). Our 
finding shows that increased NMDA-evoked currents by the acute 5-HT7 receptor activity may 
contribute to our understanding of how 5-HT7 receptors modulate synaptic plasticity. 5-HT7 
receptor-mediated increases in NMDA-evoked currents may also explain how 5-HT7 receptor 
activation potentiates bursting frequency in the CA3 hippocampal neurons (Bacon and Beck 
2000) and increases CA1 extracellular population spike amplitude in CA1 hippocampal neurons 
(Tokarski et al. 2003). Conversely, there is evidence that 5-HT7 receptor agonists decrease 
glutamate-induced increases in intracellular calcium (Smith et al. 2001) and the amplitude of 
glutamate EPSPs (Quintero and McMahon 1999). Based on the findings reported here and our 
other work describing the ability of long-term 5-HT7 receptor agonist treatment to upregulate 
PDGFβ receptors (Figure 4.9) (Vasefi et al. 2012), we propose that the activation of 5-HT7 
receptors may regulate NMDA receptor activity via two temporally distinct pathways (Figure 
2.5). Acute (5-10 min) activation of 5-HT7 receptors increases NMDA-evoked currents whereas 
long-term (2-24 h) activation of 5-HT7 receptors upregulates PDGFβ receptors, a receptor 
tyrosine kinase that inhibits NMDA receptor activity (Valenzuela et al. 1996, Vasefi et al. 
2013a). 
5-HT7 receptors are involved in aspects of learning and memory that are hippocampus dependent 
(Meneses 2004).  For example, 5-HT7 receptor knock-out mice display impaired contextual fear-
conditioning (Roberts et al. 2004) and display a reduced ability to recognize new environments 
(Sarkisyan and Hedlund 2009). These and other studies have promoted interest in 5-HT7 
receptors as a potential drug target in Alzheimer’s disease and are further supported by a study 
demonstrating an increase in memory formation by the 5-HT7 receptor agonist, AS 19 (Perez-
Garcia and Meneses 2005). NMDA receptors are crucial components of learning and memory 
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pathways in the hippocampus. Thus, the positive linkage between 5-HT7 receptors and NMDA 
receptor activity may explain how 5-HT7 receptors promote learning and memory as well as their 
involvement in LTP. 
All three 5-HT7 receptor splice variants identified in rats are positively coupled adenylate cyclase 
and display some level of constitutive activity (Leopoldo et al. 2011). Therefore it is not 
surprising that the activation of 5-HT7 receptors in hippocampal slices increases the 
phosphorylation of the NR1 subunit at serine 897. On the NR2B subunit, tyrosine 1472 is 
required/involved in CaMKII binding and activation (Nakazawa et al. 2006) and this 
phosphorylation site is linked to spinal pain transmission (Katano et al. 2011). Interestingly, 5-
HT7 receptor agonists promote pain after formalin injection in animal models (Rocha-Gonzalez 
et al. 2005). However others have found anti-nociceptive effects of 5-HT7 receptors (Dogrul and 
Seyrek 2006). These differences may be due to distinct central and peripheral pain pathways that 
contain 5-HT7 receptors. 
In summary, we have now identified two pathways downstream of 5-HT7 receptors that 
ultimately regulate NMDA receptor activity/signaling (Figure 2.5). We have demonstrated that 
the upregulation of PDGFβ receptors by long-term treatment with 5-HT7 receptor agonists is 
sufficient to protect hippocampal neurons against NMDA excitotoxicity (Figure 4.9) (Vasefi et al. 
2012; Vasefi et al. 2013a) whereas acute activation of 5-HT7 receptors increases NMDA-evoked 
currents. These findings may help to explain why previous reports identified 5-HT7 receptors as 
both positive and negative regulators of NMDA receptor signaling.  
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Figure 2.5 Proposed model for NMDA receptor regulation by short- and long-term 
activation of 5-HT7 receptors. 
Prolonged (2 to 24 h) activation of 5-HT7 receptors up regulates PDGF receptor activation and 
expression in hippocampal neurons, cortical neurons, and SH-SY5Y cells. The upregulation of 
PDGFβ receptors is sufficient to inhibit NMDA-induced neuronal cell death in primary cultures. 
In addition, NMDA receptor subunit expression is reduced. In contrast, acute (5 min) activation 
of 5-HT7 receptors increases NMDA-evoked currents and differentially regulates NMDA 
receptor subunit phosphorylation and cell surface expression. Figure modified from (Vasefi et al. 
2013a).
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Chapter 3 
Activation of 5-HT7 receptors increases neuronal platelet-
derived growth factor beta receptor expression  
3.1 Summary 
Several antipsychotics have a high affinity for 5-HT7 receptors yet despite intense interest in the 
5-HT7 receptor as a potential drug target to treat psychosis, the function and signaling properties 
of 5-HT7 receptors in neurons remain largely uncharacterized. In primary mouse hippocampal 
and cortical neurons, as well as in the SH-SY5Y cell line, incubation with 5-HT, 5-
carboxamidotryptamine (5-CT), or 5-HT7 receptor-selective agonists increases the expression of 
platelet-derived growth factor (PDGF) receptors. The increased PDGF receptor expression is 
cyclic AMP-dependent protein kinase (PKA)-dependent, suggesting that 5-HT7 receptors couple 
to Gαs in primary neurons. Interestingly, up-regulated PDGF receptors display an increased basal 
phosphorylation state at the phospholipase Cγ-activating tyrosine 1021. This novel linkage 
between the 5-HT7 receptor and the PDGF system may be an important GPCR-neurotrophic 
factor signaling pathway in neurons.	  
3.2 Introduction 
5-HT receptors can activate many intracellular signaling pathways and there are numerous 
examples of crosstalk between 5-HT receptors, growth factor receptors, and ion channels 
(Raymond et al. 2001; Shah and Catt 2004). For example, several signaling pathways between 
the 5-HT system and the platelet-derived growth factor (PDGF) receptor have been identified. In 
the mouse fibroblast cell line LMTK- transfected with the human 5-HT receptor subtype 2B, 
Nebigil et al. showed that this receptor can acutely induce PDGFRβ phosphorylation within 5 
	  	   	  38 
min (Nebigil et al. 2000), a process called transactivation. In addition, the serotonin transporter 
(5-HTT) may be involved in 5-HT-induced PDGFR activation in smooth muscle cells (Liu et al. 
2007a; Ren et al. 2010).  
Despite preliminary evidence and hypotheses for the involvement of 5-HT7 receptors in CNS 
physiology and mental health, much remains to be elucidated about 5-HT7 receptor signaling as it 
impacts brain function. Here, we demonstrate that prolonged activation of 5-HT7 in cultured 
hippocampal neurons increases the activity and expression of PDGF receptors, thereby 
establishing an additional linkage between serotonergic and neurotrophic factor signaling in 
neurons. 
3.3 Materials and Methods 
3.3.1  Reagents and antibodies 
5-HT, 5-CT, H89, LP 12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1- 
piperazinehexanamide hydrochloride), SB 269970 (R-3-(2-(2-(4-Methylpiperidin-1-yl)ethyl)-
pyrrolidine-1-sulfonyl)-phenol) and WAY 100635 (N-[2-[4-(2-methoxyphenyl)-1-
piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanene carboxamide trihydrochloride) were purchased 
from Sigma (St. Louis, MO, USA). The 5-HT7 receptor antagonists SB 258719 ((R)-3,N-
Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzene sulfonamide) was obtained 
from Tocris (Ellisville, MO, USA).  Antibodies used include those raised against PDGFβ receptor 
(Epitomics, California, USA), PDGFβ receptor phospho-tyrosine 1021 and β –actin (Santa Cruz, 
CA, USA), and α-actinin (Sigma). 
3.3.2  Cell culture 
Hippocampal and cortical neurons were isolated from E17-19 mouse fetuses (CD-1 mice, Harlan 
Lab, USA) and placed in cold dissection media (33 mM glucose, 58 mM sucrose, 30 mM 
HEPES, 5.4 mM KCl, 0.44 mM KH2PO4, 137 mM NaCl, 0.34 mM Na2HPO4, 4.2 mM NaHCO3, 
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0.03 mM phenol red, pH 7.4, 320-335 mOsm/kg). The hippocampi or cortex were digested in 
0.25% trypsin/0.1% EDTA for 30 min at 37°C. Cell mixtures were plated on collagen-coated 
culture dishes and grown at 37°C in a humidified atmosphere containing 5% CO2. Cells were fed 
twice per week with plating media (MEM, supplemented with 28 mM glucose, 5.4 mM NaHCO3, 
100 units/ml insulin, 10% fetal bovine serum, 10% horse serum, pH 7.6, 320-335 mOsm/kg) for 
the first week and with feeding media (plating media without serum) in subsequent weeks. FUDR 
(0.081 mM 5-fluoro-2-deoxyuridine (Sigma) and 0.2 mM uridine to MEM), a mitotic inhibitor, 
was added 3-5 days after and drug treatments were performed 14 to 21 days after plating. For SH-
SY5Y cells, cells were plated in 6-well culture plates with complete growth media consisting of 
DMEM and Ham’s F12 (Thermo, Fisher, Markham, Ontario) in a 1:1 ratio, supplemented with 
2.5 mM glutamate, and 10% fetal bovine serum (Sigma). Upon reaching confluency, cells were 
serum-deprived for 24 h prior to drug treatments. 
3.3.3 Real-time PCR analysis 
RNA isolation (BioRad Aurum RNA Mini kit) and reverse transcription (iScript cDNA synthesis 
kit; BioRad, Hercules CA) were used on extracts of primary hippocampal neurons. Primers for 
the PDGFβ receptor (forward primer 5'- GCG GGT GGT GTT CGA GGC TTA T -3', 5'- CCT 
GTG GCT CAA GGA CAA CCG T -3' and reverse primer 5'- AGG TCT CTG CAG GTA GAC 
CAG GTG -3', 5'- GAG GTC TCT GCA GGT AGA CCA GGT -3', IDT, San Diego, California, 
USA) were used to determine PDGFβ receptor mRNA expression and levels were normalized to 
β-actin expression. SSO Fast EvaGreen real-time PCR supermix was purchased from BioRad. 
3.3.4  Western blot and analysis 
After drug treatment, cells were washed with chilled PBS, and lysed in chilled lysis buffer (20 
mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 30 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, and 1% triton-X-100; 
supplemented with Halt Protease and Phosphatase Inhibitor (Thermo, Fisher, Markham, Ontario) 
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prior to use. Cell lysates were subjected to SDS-PAGE and proteins were transferred to 
nitrocellulose membranes. Membranes were blocked, washed, incubated with primary and 
secondary antibodies and visualized by the enhanced chemiluminescence using the 
chemiluminescent substrate (Millipore, Etobicoke, Ontario). Statistical analysis of the data was 
completed using the Prism® GraphPad program. 
 
3.3.5  Animals 
All animal experiments were performed in agreement with the guidelines of the policies on the 
Use of Animal at the University of Waterloo. 
 
3.4 Results and Discussion 
In cultured hippocampal neurons, treatment with 5-carboxamidotryptamine (5-CT), a 5-HT1, 5, 
and 7-selective agonist (Voronezhskaya et al. 2008) increased PDGFβ receptor expression to a 
greater extent than 5-HT itself (Figure 3.1A). The increase in PDGFβ receptor expression by 5-
CT was dose dependent with a maximal effect observed at a concentration of 50 nM (Figure 
3.1C). 24 h incubation robustly increased PDGFβ receptor expression and an increase in PDGFβ 
receptor levels was detected as early as 2 h after application of 5-CT to the hippocampal cultures 
(Figure 3.1D). Although 5-HT7 receptors are expressed in both neurons and non-neuronal cells, 
the PDGFβ receptor is expressed primarily in pyramidal neurons in the hippocampus. (Beazely et 
al. 2009; Smits et al. 1991). GPCRs such as D2-class dopamine receptors can transactivate 
PDGFβ receptors, a rapid (3-10 min) process that leads to a phosphorylation of the PDGF 
receptor and activates downstream signaling pathways, including a phosphorylation of mitogen-
activated protein kinase (MAPK) and inhibition of NMDA receptor currents (Beazely et al. 2006; 
Kotecha et al. 2002; Oak et al. 2001).  
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Although more subtype-selective than 5-HT, 5-CT also activates 5-HT1 and 5-HT5 receptors 
(Voronezhskaya et al. 2008). To further identify the specific 5-HT receptor subtype mediating the 
increase in PDGFβ receptor expression, we first examined the ability of 5-CT to increase PDGFβ 
receptor levels in the presence of the 5-HT1A antagonist, WAY 100635. WAY 100635, applied 
30 min prior to the application of 5-CT, did not block the increase in PDGFβ receptor expression 
(Figure 3.2A, B). Interestingly, WAY 100635 alone increased PDGFβ receptor expression, and 
WAY 100635 + 5-CT together additively enhanced PDGFβ receptor expression (Figure 3.2A, B). 
We next incubated hippocampal cultures with the cyclic AMP-dependent protein kinase (PKA) 
inhibitor, H89. H89 blocked the upregulation of PDGFβ receptor by 5-CT (Figure 3.2C, 3D), 
suggesting that the serotonin receptor responsible for PDGFβ receptor upregulation is coupled to 
Gαs and an increase in cyclic AMP levels. Furthermore, application of the direct adenylate 
cyclase activator, forskolin (10 µM) also increased PDGFβ receptor expression and activation in 
primary hippocampal cells (Figure 3.3A, B). 
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Figure 3.1 Activation of 5-HT receptors in primary hippocampal neurons increases 
the expression of PDGFβ receptors. 
A) Primary hippocampal neurons were treated with 50 nM 5-CT or 50 nM 5-HT for 24 h. The 
increase in the expression level of PDGFβ receptors is expressed as a fold change vs. vehicle-
treated neurons (control).  Data represented the average and standard error of 6 independent 
experiments.  * p < 0.05, Student’s unpaired t-test.  B) Western blots showing PDGFβ receptor 
expression and α-actinin expression as a loading control.  C) Concentrations of 10-1000 nM 5-CT 
were added to hippocampal cultures for 24 h.  The fold-change in PDGFβ receptor expression 
was determined by quantification of Western blots, n = 5-7. * p < 0.05, ANOVA analysis with 
Dunnett’s post-test.  D) Hippocampal cultures were incubated with 50 nM 5-CT for 2-24 h. The 
fold-change in PDGFβ receptor expression was determined by quantification of Western blots, n 
= 5. (* p < 0.05, ANOVA analysis with Dunnett’s post-test).
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The ability of H89, but not WAY 100635, to block 5-CT-mediated increases in PDGFβ receptor 
expression suggests that the Gαs-coupled 5-HT7 receptor may be responsible for mediating the 
increase in PDGFβ receptor expression. To investigate this we employed the 5-HT7 receptor-
selective agonist LP 12 (Leopoldo et al. 2008), the 5-HT7 receptor inverse agonist, SB 269970 
(Mahe et al. 2004b), and the neutral antagonist SB 258719 (Mahe et al. 2004b). Similar to 5-CT, 
24 h treatment of hippocampal neurons with 300 nM LP 12 increased PDGFβ receptor expression 
and this increase was blocked by SB 269970 (Figure 3.4A) and by SB 258719 (Figure 3.4B). 
Both SB 269970 and SB 258719 also blocked 5-CT-induced increases in PDGFβ receptor 
expression. In addition to increasing PDGFβ receptor expression, PDGFβ receptor mRNA levels 
were also increased by nearly 45% in primary hippocampal neurons (Figure 3.4C). Interestingly, 
the time-course of LP 12 administration displayed a bimodal effect on PDGFβ receptor 
expression, with significant increases at 8 h and then again at 24 h (Figure 3.4D). However, The 
LP 12 administration time-course showed a significant increase on PDGFβ receptor expression at 
24 h in the cortical culture (Figure 3.5A) and at 4h and 24 h in the SH-SY5Y cells (Figure 3.5B).  
LP 12 has a very high affinity for 5-HT7 receptors (Ki = 0.13 nM) (Leopoldo et al. 2007). 
However we observed the greatest increases in PDGFβ receptor expression at 300 nM in both 
hippocampal and cortical neurons, and at 200 nM in the SH-SY5Y cells. At a concentration of 
300 nM, we would expect significant binding to both 5-HT1A receptors (Ki = 61 nM) (Leopoldo 
et al. 2007) as well as D2 dopamine receptors (Ki = 224 nM) (Leopoldo et al. 2007). However 
the ability of both 5-CT and LP 12 to increase PDGFβ receptor expression, the inability of the 5-
HT1A receptor antagonist, WAY 100635 to block these effects, and the complete inhibition of 
both LP-12- and 5-CT-induced increases in PDGFβ receptor expression by the 5-HT7 antagonists 
SB 269970 and SB 258719 suggests that the observations reported herein are indeed mediated by 
the 5-HT7 receptor. 
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Figure 3.2 5-CT-induced up-regulation of PDGFβ receptor is PKA-dependent and 
5-HT1A receptor-independent. 
A-D) Cultured hippocampal neurons were incubated overnight with 5-CT (50 nM) with or 
without or 1 µM WAY100635 (A, B) or 10 µM H89 (C, D) to antagonize 5-HT1A receptors or to 
inhibit PKA, respectively.  5-CT increased PDGFβ receptor expression to control (* p < 0.05 vs. 
control, ** p < 0.05 vs. 5-CT-treated cells, ANOVA analysis with Bonferroni’s post-test, n = 8 
for experiments A, B and n = 5 for experiments C, D). B and D show representative blots for the 
data presented in A and C. n = 8 for experiments A, B and n = 5 for experiments C, D. 
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Figure 3.3 Forskolin up regulates PDGFβ receptor expression in hippocampal 
culture. 
A-C) Cultured hippocampal neurons were incubated overnight with LP 12 (300 nM) and 
forskolin (10 µM). Forskolin increased PDGFβ receptor expression (A) and activation at Y1021 
(B) in the hippocampal culture n = 3. (* p < 0.05, ANOVA analysis with Dunnett’s post-test). C 
shows representative blots for the data presented in A and B.  
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Figure 3.4 5-HT7 receptor activation increases PDGFβ receptor expression in 
primary hippocampal neurons. 
A) Hippocampal neurons were incubated for 24 h with LP 12 (300 nM) with or without or 1 µM 
SB 269970, a 5-HT7 receptor inverse agonist. LP 12 increased PDGFβ receptor expression and 
this was reduced by co-incubation with SB 269970 (n = 7). * p < 0.01, ANOVA analysis with 
Dunnett’s post-test. B) LP 12 (300 nM) was added to hippocampal cultures for 24 h in the 
presence or absence of the neutral 5-HT7 receptor antagonist SB 258719 (1 µM, n = 5). * p < 
0.05, ANOVA analysis with Dunnett’s post-test. INSETs: Representative western blots showing 
PDGFβ receptor expression and β-actin as a loading control.  C) Hippocampal cultures were 
incubated with vehicle or 300 nM LP 12 for 24 h. The mRNA was isolated using Aurum RNA 
Mini kit. PDGFβ receptor mRNA levels were normalized to β-actin.  * p < 0.05, Student’s 
unpaired t-test.  D) Hippocampal cultures were incubated with 300 nM LP 12 for 4-24 h. The 
fold-change in PDGFβ receptor expression was determined by quantification of Western blots, n 
= 3. (* p < 0.05, ANOVA analysis with Dunnett’s post-test). 




Figure 3.5 5-HT7 receptor activation increases the expression of PDGFβ receptor 
in cortical culture and SH-SY5Y cells for 24 h. 
The cortical cultures (A) and SH-SY5Y cells (B) were incubated with 300 nM LP12 for 0–24 h. 
The fold-change in PDGFβ receptor expression was determined by quantification of Western 
blots, n = 3 (*p < 0.05, ANOVA with Dunnett’s post-test). 
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PDGFβ receptors are expressed throughout the CNS, including the hippocampus (Beazely et al. 
2009) and the cortex (Beazely et al. 2009). In primary cortical neurons, 24 h incubation with LP 
12 increases PDGFβ receptor expression and is blocked by SB 258719 (Figure 3.6A). Similar 
results were observed in the SH-SY5Y cell line (Figure 3.6B). Similar to primary hippocampal 
neurons, maximal effects on PDGFβ receptor expression were observed at 300 nM LP 12 in 
primary cortical neurons and 200 nM LP 12 in SH-SY5Y cells (Figure 3.7A, B).  
PDGFβ receptors are receptor tyrosine kinases that activate numerous intracellular signaling 
pathways when the receptor is phosphorylated at specific tyrosine residues (Heldin et al. 1998). 
Phosphorylation of PDGFβ receptors at the PLCγ-activating tyrosine 1021 is associated with the 
inhibition of NMDA receptor currents (Beazely et al. 2009; Lei et al. 1999; Valenzuela et al. 
1996) and is one of the most robust phosphorylation sites for PDGFβ receptors transactivated by 
dopamine receptors in the hippocampus and prefrontal cortex (Beazely et al. 2006). To determine 
if the PDGFβ receptors, after upregulation by 5-HT7 receptors, have a higher basal 
phosphorylation we monitored the phosphorylation state at Y1021. In addition to an increase in 
receptor expression, the basal Y1021 phosphorylation of PDGFβ receptors is much higher after 
LP 12 incubation of hippocampal cultures (Figure 3.8). Similar results were observed with 5-CT 
in hippocampal cultures and with LP 12 in cortical cultures and SH-SY5Y cells (Figure 3.9A, B). 
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Figure 3.6 5-HT7 receptor activation increases PDGFβ receptor expression in 
primary cortical neurons and SH-SY5Y cells. 
A) LP 12 (300 nM) was added to cortical cultures for 24 h in the presence or absence of the 
neutral 5-HT7 receptor antagonist SB 258719 (1 µM, n = 4). * p < 0.05, ANOVA analysis with 
Dunnett’s post-test INSET: Representative western blots. B) LP 12 (300 nM) was added to SH-
SY5Y cells for 24 h in the presence or absence of the neutral 5-HT7 receptor antagonist SB 
258719 (1 µM, n = 5). * p < 0.05, ANOVA analysis with Dunnett’s post-test INSET: 
Representative western blots. 




Figure 3.7 Activation of 5-HT7 receptor in cortical culture and SH-SY5Y cell line is 
dose dependent. 
Concentrations of 1-400 nM LP12 were added to the cultures for 24 h.  The fold-change in 
PDGFβ receptor expression was determined by quantification of Western blots, n = 5-7. * p < 
0.05, ANOVA analysis with Dunnett’s post-test. 
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Figure 3.8 The basal activity level of up-regulated PDGFβ receptors is increased. 
A, B) Cultured hippocampal neurons were incubated overnight with LP 12 (300 nM) with or 
without or 1 µM SB 258719, a selective 5-HT7 receptor antagonist. Western blot membranes 
were probed with anti-PDGFβ receptor antibodies, stripped, and reprobed with anti-phospho-
1021 PDGFβ receptor antibodies.  Blots are representative of 7 independent experiments. * p < 
0.05, ANOVA analysis with Dunnett’s post-test. 
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Figure 3.9 5-HT7 receptor activation increases the expression of PDGFβ receptor 
in cortical culture and SH-SY5Y cells. 
The cells were incubated overnight with LP 12 (300 nM) with or without or 1 µM SB 258719, a 
selective 5-HT7 receptor antagonist. Western blot membranes were probed with anti-PDGFβ 
receptor antibodies.  Blots are representative of 8 independent experiments. * p < 0.05, ANOVA 
analysis with Dunnett’s post-test. 
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There are several lines of evidence linking the 5-HT system to growth factor receptor signaling. 
As noted by Andrae et al. in their review, “little is known about PDGF receptors transcriptional 
regulation” (Andrae et al. 2008). This report suggests that PDGFβ receptor expression, at least in 
hippocampal and cortical neurons and SH-SY5Y, may be cyclic AMP-dependent and regulated 
by 5-HT7 receptors. We have identified the 5-HT7 receptor as a regulator of PDGFβ receptor 
expression. Activation of 5-HT7 receptors increases PDGFβ receptor expression and increases 
the basal activity of the receptor in hippocampal and cortical neurons and in the SH-SY5Y cell 
line.  
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Chapter 4 
5-HT7 receptor neuroprotection against NMDA-induced 
excitotoxicity is PDGFβ receptor-dependent 
4.1 Summary 
The serotonin (5-HT) type 7 receptor is expressed throughout the CNS including the 
hippocampus. Long-term (2-24 h) activation of 5-HT7 receptors regulates growth factor receptor 
expression, including the expression of PDGFβ receptors. Direct activation of PDGFβ receptors 
in hippocampal and cortical neurons as well as primary neurons inhibits N-methyl-D-aspartate 
(NMDA) receptor activity and attenuates NMDA receptor-induced neurotoxicity. Our objective 
was to investigate whether the 5-HT7 receptor-induced increase in PDGFβ receptor expression 
would be similarly neuroprotective. We demonstrate that 5-HT7 receptor agonist treatment in 
primary hippocampal neurons also increases the expression of phospholipase C (PLC) γ, a 
downstream effector of PDGFβ receptors associated with the inhibition of NMDA receptor 
activity. To determine if the upregulation of PDGFβ receptors is neuroprotective, primary 
hippocampal neurons were incubated with the 5-HT7 receptor agonist LP 12 for 24 h. Indeed, LP 
12 treatment prevented NMDA-induced neurotoxicity and this effect was dependent on PDGFβ 
receptor kinase activity. Treatment of primary neurons with LP 12 also differentially altered 
NMDA receptor subunit expression, reducing the expression of NR1 and NR2B, but not NR2A. 
These findings demonstrate the potential for providing growth factor-dependent neuroprotective 
effects using small molecule G protein-coupled receptors ligands. 
	  
4.2 Introduction 
Clinically used antipsychotic drugs antagonize 5-HT7 receptors and compounds with 5-HT7 
receptor antagonist activity have been investigated as potential treatments for schizophrenia and 
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other psychoses (Uzun et al. 2005; Galici et al. 2008) and clinical trials are ongoing with novel 5-
HT7 receptor antagonists, JNJ-18038683 and Lu AA21004, to treat depression (Bonaventure et 
al. 2012; Mork et al. 2012). Despite intense clinical research into drugs that activate or 
antagonize 5-HT7 receptors, very little is known about their molecular pharmacology, 
particularly their signaling roles in neurons. With respect to neuronal activity 5-HT7 receptors are 
reported to increase excitability in the hippocampus, possibly by decreasing slow 
afterhyperpolarizations (sAHPs) (Bacon and Beck 2000; Tokarski et al. 2005) or by inhibiting 
calcium-dependent potassium channels (Gill et al. 2002). 5-HT7 receptors have also been linked 
to the stimulation of afterdepolarizations in the thalamus (Chapin and Andrade 2001a; Chapin 
and Andrade 2001b). Thus, there is evidence that 5-HT7 receptors can significantly affect 
neuronal activity but the molecular mechanisms remain unknown.  
We have demonstrated that 2-24 h 5-HT7 receptor agonist treatment increases the expression of 
PDGFβ receptors in primary hippocampal and cortical neurons, as well as in the SH-SY5Y cell 
line. The upregulated PDGFβ receptors displayed an increase in basal phosphorylation at tyrosine 
1021, the PLCγ docking site and the phosphorylation site associated with PDGF-induced 
inhibition of NMDA-evoked currents (Valenzuela et al. 1996; Beazely et al. 2009; Vasefi et al. 
2012). Both the expression of PDGFβ receptors and the increase in their phosphorylation level 
were maximally increased after 24 h incubation, but increases were observed as early as 2 h. 
The expression of the PDGF ligands, PDGF-A and -B mRNA and the PDGF-BB and -AB protein 
levels are increased in neurons and support cells surrounding areas damaged during ischemic 
events (Krupinski et al. 1997). In addition to PDGFβ receptor and PDGF-B chain expression 
being upregulated after ischemic events, exogenously-applied PDGF-BB is also neuroprotective 
in focal ischemia (Sakata et al. 1998) and against glutamate- and N-methyl-D-aspartate (NMDA)-
induced cell death in hippocampal neurons (Tseng and Dichter 2005; Egawa-Tsuzuki et al. 2004). 
We have demonstrated previously that PDGFβ receptors selectively inhibit NR2B-containing 
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NMDA receptor currents and that PDGFβ receptor-mediated neuroprotection against NMDA-
induced toxicity is associated with the inhibition of NR2B-containing NMDA receptors (Beazely 
et al. 2009). Acute treatment of hippocampal slices with PDGF-BB also selectively reduces the 
cell surface localization of the NR1 and NR2B NMDA receptor subunits, but not NR2A (Beazely 
et al. 2009). 
There are several challenges involved in the clinical use of growth factors to treat CNS disorders. 
Growth factors are proteins that are relatively large (compared to small molecule drugs) which 
prevents both oral administration and their ability to passively cross the blood-brain barrier. 
Given the ability of 5-HT7 receptor agonists to upregulate the expression and basal 
phosphorylation of PDGFβ receptors, our objective was to determine if simply upregulating 
PDGFβ receptors would result in neuroprotective effects against NMDA-induced toxicity. We 
demonstrate that the 5-HT7 agonist LP 12 increased PDGFβ receptor expression on pyramidal 
neurons in primary hippocampal cultures and LP 12 treatment for 24 h prevented NMDA-induced 
cell death in a PDGFβ receptor-dependent manner. Interestingly, 5-HT7 receptor activation 
decreased the expression of NR1 and NR2B NMDA receptor subunits but not the expression of 
NR2A. Thus, 5-HT7 receptor activation reduces NR2B expression and increases the expression 
of the PDGFβ receptor, a selective inhibitor of NR2B-containing NMDA receptors. 
4.3 Materials and Methods 
Reagents and antibodies – LP 12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1- 
piperazinehexanamide hydrochloride), NMDA (N-methyl-D-aspartate), PDGF-BB, glycine, and 
other chemical reagents were purchased from Sigma (St. Louis, MO, USA). AG1296 (6,7-
Dimethoxy-2-phenylquinoxaline) and Ro 25-6981 ((αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-
(phenylmethyl)-1-piperidinepropanol maleate) were purchased from Cedarlane (Burlington, ON). 
Imatinib mesylate (STI-571) (4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
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pyridinyl)-2-pyrimidinyl]amino]phenyl]-methanesulfonate-benzamide) was purchased from 
Novartis (Basel, Switzerland). The 5-HT7 receptor antagonists SB 258719 ((R)-3,N-Dimethyl-N-
[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzene sulfonamide) and SB 269970 ((2R)-1-[(3-
Hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl] pyrrolidine hydrochloride) were 
obtained from Tocris (Ellisville, MO, USA). Antibodies used include those raised against PDGFβ 
receptor (Epitomics, California, USA), PDGFβ receptor phospho-tyrosine 1021, PLCγ, β-actin 
(Santa Cruz, CA, USA), anti-NR1, anti-NR2A, and anti-NR2B (EMD Millipore, Billerica, MA). 
All secondary antibodies including Dylight 488 were obtained from Fisher (Ottawa, ON). 
Primary cell culture - Hippocampal neurons were isolated from E17-19 fetuses and placed in cold 
dissection media (33 mM glucose, 58 mM sucrose, 30 mM HEPES, 5.4 mM KCl, 0.44 mM 
KH2PO4, 137 mM NaCl, 0.34 mM Na2HPO4, 4.2 mM NaHCO3, 0.03 mM phenol red, pH 7.4, 
320-335 mOsm/kg). The hippocampi were separated from the brain and digested in 0.25% 
trypsin/0.1% EDTA for 20 min at 37°C. The resulting cell mixtures were plated on poly-D-lysine 
(PDL) (Sigma) coated culture dishes and grown at 37°C in a humidified atmosphere containing 
5% CO2. Cells were plated in plating media (DMEM (Fisher), 10% fetal bovine serum (FBS) and 
10% horse serum (HS) (Sigma)) and fed twice per week with feeding media (Neurobasal media 
supplemented with B27 (Life Technologies, Burlington, ON)). FUDR (0.081 mM 5-fluoro-2-
deoxyuridine) and 0.2 mM uridine (Sigma) were added 3-5 days after plating for 24 h once the 
cells reached confluency to inhibit the growth of non-neuronal cells. Drug treatments were 
performed 10 to 14 days after plating. 
Western blot - After drug treatment, cells were washed with chilled phosphate-buffered saline 
(PBS), and lysed in chilled lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 30 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium 
orthovanadate, and 1% Triton X-100; supplemented with Halt Protease and Phosphatase Inhibitor 
(Thermo, Fisher, Markham, Ontario) prior to use). For NMDA receptor subunit blotting, lysis 
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buffer was supplemented with 1% SDS and 1% Triton X100 to solubilize the receptors. Cells 
were scraped, homogenized and centrifuged at 14,000 x g for 20 min at 4°C and the supernatant 
was collected. Homogenates were subjected to SDS-PAGE and proteins were transferred to 
nitrocellulose membranes, blocked with 5% non-fat dry milk in Tris-buffered saline and 0.1% 
Tween-20 for 1 h at room temperature or overnight at 4°C, and incubated in primary antibodies 
for 1 h at room temperature or overnight at 4°C. Membranes were washed three times in Tris-
buffered saline with 0.1% Tween-20, incubated with HRP-conjugated secondary antibodies for 1 
h at room temperature, washed again, and bound antibodies were visualized by the enhanced 
chemiluminescence using Luminata Crescendo substrate (Millipore, Etobicoke, Ontario). Images 
of Western blots were taken on a Kodak 4000MM Pro Imaging Station, and densitometric 
analyses were performed using Kodak Molecular Imaging software. Membranes were then 
stripped and reprobed with additional antibodies. 
Immunofluorescence - Primary hippocampal neurons were grown on sterile coverslips in Petri 
dishes and treated with LP 12 for 24 h. Hippocampal neurons were fixed by 4% (w/v) 
paraformaldehyde (Sigma) for 15 min and rinsed three times with PBS. The cultures were 
permeabilized using 0.3% Triton X-100 (Sigma) for 15 min and then washed with PBS. 
Hippocampal neurons were blocked in 4% (w/v) bovine serum albumin (Rockland, Gilbertsville, 
PA) for 1 h and incubated with primary antibody overnight with agitation at 4°C. The coverslips 
were washed three times with PBS, labeled with secondary antibody (Dylight 488) at 1:2000 
(Thermo) for 1 h, mounted with Prolong Gold antifade solution with DAPI (Invitrogen, Carlsbad, 
CA), and visualized on Zeiss Axiovert 200 microscope and LSM 510 META software (Carl Zeiss 
Canada Ltd., Mississauga, ON) with 63x oil-based objective.  
MAP2 cell death assay - 10-14-day-old hippocampal neurons on 12-well plates were pretreated 
for 24 h with drugs, washed, and incubated with vehicle or NMDA/glycine for 5 min. The cells 
were washed and returned to culture medium overnight. After 24 h, cells were fixed in 4% 
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paraformaldehyde in PBS, permeabilized with 0.4% Triton in PBS, blocked for 30 min with 10% 
bovine serum albumin in PBS, and incubated with anti-MAP2 antibodies (1:5000, Sigma) 
overnight at 4 °C. The following day, the cells were washed in 0.4% Triton/PBS three times and 
incubated with anti-mouse IgG horseradish peroxidase-conjugated antibody (Amplex Elisa 
Development Kit, Molecular Probes). Cells were washed three times and incubated with Amplex 
UltraRed substrate for 30 min. The reaction was then terminated with Amplex UltraRed Stop 
Solution. Absorption at 565 nm was measured and data were normalized to control samples. 
MTT toxicity assay - Hippocampal neurons were plated at density of 4 x 105 per mL in 96-well 
plates and grown for 10-14 days. The cells were pretreated with drugs for 24 h and exposed to 
NMDA/glycine for 5 min. Cells were washed and incubated in feeding media for 24 h. MTT in 
an amount equal to 10% of the culture medium volume was added to each well and the cells were 
incubated for additional 3 h at 37 °C in 5% CO2. After incubation, the resulting formazan crystals 
were solubilized with MTT reagent solution (10% Triton X-100 and 0.1 N HCl in anhydrous 
isopropanol) in each well and the absorbance was recorded at 570 nm. All results were expressed 
as a percent reduction of MTT relative to untreated controls. 
Statistical Analysis - Statistical analysis of the data was completed using Prism® GraphPad 
program. All data is reported as mean ± SEM. Significance level is set at α = 0.05. Data was 
analyzed by one-way ANOVA. 
Animals - All animal experiments were performed in agreement with the guidelines of the 
policies on the Use of Animal at the University of Waterloo. All animal protocols were approved 
by the University of Waterloo animal care committee. 
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4.4 Results 
We recently reported that long-term (2-24 h) activation of 5-HT7 receptors with 5-HT, 5-
carboxamidotryptamine (5-CT), or the 5-HT7-selective agonist, LP 12 (Leopoldo et al. 2008), 
increased PDGFβ receptor expression in primary mouse hippocampal and cortical neurons and in 
SH-SY5Y cells (Figure 3.4A, B and 3.6) (Vasefi et al. 2012). The increase in PDGFβ receptor 
expression after LP 12 incubation was dose-dependent with significant increases observed at 
concentrations of 100 and 300 nM (Figure 4.1A, D). 
The increased expression of PDGFβ receptors was accompanied by an increase in the basal 
PDGFβ receptor phosphorylation state at tyrosine 1021 (Figure 3.8, Vasefi et al. 2012) as well as 
other tyrosine residues (tyrosine 1009 and tyrosine 771). Similar to PDGFβ receptor expression, 
tyrosine 1021 phosphorylation was maximally increased at 300 nM LP 12 (Figure 3A, B). Similar 
to other Gαs-coupled receptors, 5-HT7 receptors are reported to be internalized and down-
regulate after exposure to agonist (Krobert et al. 2001). Interestingly, despite the fact that LP 12 
has a reported affinity of 0.13 nM for the 5-HT7 receptor, we only observed a significant 
reduction in 5-HT7 receptor expression after 24 h treatment with 300 nM LP 12 (Figure 4.1C, D), 
the same concentration that maximally increased the expression of PDGFβ receptors. LP 12 also 
increased the expression of phospholipase C (PLC) γ, ERK, and CREB in primary hippocampal 
cultures and this increase was blocked by the 5-HT7 receptor antagonist SB 258719 (1 µM) 
(Figure 4.2A, B and 4.3A, C). 
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Figure 4.1 Effect of LP 12 on PDGFβ  and 5-HT7 receptor in primary hippocampal 
neurons. 
A) Neurons were treated with 10 nM to 1 µM LP 12 for 24 h. The level of PDGFβ receptor 
expression is displayed as a fold change vs. vehicle-treated neurons. Immunoreactivity for the 
PDGFβ receptor was normalized to β-actin. n = 3 * p < 0.05, ** p < 0.01, ANOVA analysis with 
Dunnett’s post-test. B) Neurons were treated as in A. The phosphorylation of the PDGFβ 
receptors was determined using an anti-phospho-Y1021 PDGFβ receptor antibody and was 
normalized to total PDFGβ receptor expression. n = 3 * p < 0.05, ANOVA analysis with 
Dunnett’s post-test. C) Neurons were treated as in A and B.  Immunoreactivity for the 5-HT7 
receptor was normalized to β-actin. n = 4 ** < 0.01, ANOVA analysis with Dunnett’s post-test. 
D) Representative Western blots for the PDGFβ receptor, phospho-Y1021, the 5-HT7 receptor, 
and β-actin. 






Figure 4.2 Effect of LP 12 on PLCγ  expression in primary hippocampal culture. 
Hippocampal cultures were treated with vehicle or 300 nM LP 12, 1 µM SB 258719, or both for 
24 h. The level of PLCγ expression is expressed as the fold change vs. vehicle-treated cells. 
Immunoreactivity for PLCγ was normalized to β-actin, n = 3 * p < 0.05 vehicle vs. LP 12, # p < 
0.05 LP 12 vs. LP 12 + SB 258719, ANOVA analysis with Bonferroni’s post-test. Representative 
Western blots are shown. 
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Figure 4.3 The 5-HT7 receptor activation increases expression of ERK and CREB. 
The hippocampal cultures were treated with LP 12 (300nM) for 24 h with or without or 1 µM SB 
258719, a selective 5-HT7 receptor antagonist. Western blot membranes were probed with anti-
ERK antibodies (A, B) and anti-CREB antibodies (C, D).  Blots are representative of 8 
independent experiments. * p < 0.05, ANOVA analysis with Dunnett’s post-test.
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Figure 4.4 LP 12 increases PDGFβ  receptor expression in pyramidal neurons in 
primary hippocampal cultures. 
Cells were cultured on glass coverslips and maintained at 37ºC for 14-21 days in vitro at which 
time cells were treated with the control (vehicle) or with 300 nM LP 12 (LP 12) for 24 h. Nuclei 
were directly stained with DAPI (blue) and the PDGF receptors were detected with an anti-PDGF 
receptor antibody and secondary antibody conjugated to Dylight 488 (green). For the LP 12-
treated images, the red arrow indicates a non-neuronal cell, which shows a DAPI-stained nucleus 
without PDGFβ receptor immunoreactivity. The images displayed are representative of six 
independent experiments. 
	  	   	  65 
 
There are two PDGF receptor isoforms, α and β, and in the hippocampus, the β isoform appears is 
primarily expressed in pyramidal neurons (Smits et al. 2001; Beazely et al. 2009). PDGFβ 
receptors do not appear to significantly colocalize with PSD-95 or the NR2A subunit of the 
NMDA receptor, but have a relatively higher colocalization with the NR2B subunit (Beazely et al 
2009.). To qualitatively assess if the expression pattern of PDGFβ receptors after 24 h LP 12 
treatment displayed a similar expression pattern compared to untreated cells, primary 
hippocampal neurons were treated for 24 h with vehicle or 300 nM LP 12, fixed, and incubated 
with anti-PDGFβ receptor antibodies. After LP 12 treatment, PDGFβ receptor expression was 
still observed primarily on pyramidal neurons compared to non-neuronal cells (Figure 4.4). 
Similar to our previous results, PDGFβ receptors were expressed on both neuronal cell bodies and 
processes. 
Direct activation of PDGFβ receptors by PDGF-BB produces neuroprotective effects in cultured 
hippocampal neurons against glutamate- and NMDA-induced neurotoxicity (Tseng and Dichter 
2005; Beazely et al. 2009). To determine if 24 h treatment with LP 12 could similarly promote 
neuroprotective effects by upregulating PDGFβ receptor expression we incubated primary 
hippocampal neurons for 24 h with 300 nM LP 12 followed by 100 µM NMDA/1 µM glycine for 
10 min. 24 h post-NMDA treatment we measured the remaining number of live cells using both 
MTT (Figure 4.5A) and MAP2 (Figure 4.5B) assays (Carrier et al. 2006; Beazely et al. 2009). As 
a positive control we also treated neurons with PDGF-BB (10 ng/mL) for 10 min to directly 
activate PDGFβ receptors prior to NMDA treatment (Figure 4.5A). LP 12 treatment for 24 h was 
indeed able to prevent NMDA-induced cell death (Figures 4.5A, B). To determine if the 
neuroprotective effects of LP 12 required PDGFβ receptor activity we repeated the cell death 
assay in the absence or presence of PDGFβ receptor kinase inhibitors. STI-571 inhibits PDGFβ 
receptor kinase activity in vitro with an IC50 value of ~100 nM (Roussidis et al. 2007) and 
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inhibits PDGFβ receptor signaling with an IC50 value in the mid-µM range (Roussidis et al. 
2007; Weigel et al. 2009). STI-571 attenuated the neuroprotective effects of LP 12 at 
concentrations of 1 and 5 µM (Figure 4.5C). Similarly, AG1296 prevented LP 12 induced cell 
death at 5 µM, a concentrations similar to its IC50 for inhibiting PDGF-induced cell proliferation 
(Kovalenko et al. 1994) (Figure 4.4D). Both STI-571 and AG1296 blocked the neuroprotective 
effects elicited by LP 12, suggesting that these neuroprotective effects are PDGFβ receptor-
dependent. 
The neuroprotective effects elicited by LP 12 were similar to those observed in neurons pretreated 
with the NR2B subunit-selective antagonist, Ro 25-6981 (Beazely et al. 2009) (Figure 4.6).  
5-HT7 receptor activation increases PDGFβ receptor and PLCγ expression and reduces the 
expression of 5-HT7 receptors as shown in Figure 4.1 and 4.2. Other 5-HT receptor subtypes 
have been shown to differentially affect the expression of NMDA receptor subunits. For example, 
in vivo, treatment with the 5-HT6 receptor ligand, SB-271047, differentially alters NMDA 
receptor subunit expression in the striatum (Marcos et al. 2010). To determine if the application 
of 5-HT7 receptor agonists altered NMDA receptor subunit expression in primary hippocampal 
neurons we applied 300 nM LP 12 for 24 h. 5-HT7 receptor activation reduced the expression of 
the NR1 and NR2B subunits but not the expression of NR2A (Figure 4.7). The changes in NR1 
and NR2B expression were blocked by the 5-HT7 receptor antagonist, SB 258719 (1 µM, Figure 
4.7A, B, E, F). To determine if the observed change in NR2B subunit expression was due to the 
activation of the PDGFβ receptor we incubated the neurons with LP 12 in the absence or presence 
of STI-571. STI-571 prevented LP 12-induced decreases in both NR1 and NR2B subunit 
expression (Figure 4.8). 
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Figure 4.5 Activation of 5-HT7 receptors is neuroprotective via PDGFβ  receptor 
activity. 
Hippocampal cultures were pretreated with vehicle or 300 nM LP 12 for 24 h followed by 100 
µM NMDA/1 µM glycine for 10 min. For the PDGF-BB bar, 10 ng/ml PDGF-BB was added for 
10 min prior to NMDA treatment. The number of cells was determined 24 h later by both MTT 
(A, n = 8) and MAP2 (B, n = 7) assays. Panel A, *** p < 0.001, vehicle vs. NMDA, #, p < 0.05, 
NMDA vs. NMDA + LP, ANOVA analysis with Bonferroni’s post-test (For PDGF-BB, the last 
bar in panel A is a single, representative experimental result). Panel B, * p < 0.05, vehicle vs. 
NMDA, #, p < 0.01, NMDA vs. NMDA + LP, ANOVA analysis with Bonferroni’s post-test. To 
determine if the neuroprotective effects of the 5-HT7 receptor agonist required PDGFβ receptor 
kinase activity, cultures were co-pretreated with 1 or 5 µM STI-571 (C, n = 13) or 1, 2.5, or 5 µM 
AG1296 (D, n = 4) and 300 nM LP 12 for 24 h followed by 100 µM NMDA/1 µM glycine for 10 
min. Cell viability was determined 24 h later by MTT assay. Panel C and D, * p < 0.05, ** p < 
0.01 compared to vehicle, ANOVA analysis with Dunnett’s post-test. 
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Figure 4.6 Activation of 5-HT7 receptors is neuroprotective similar to NR2B 
subunit-selective antagonist, Ro 25-6981.  
To determine if the neuroprotective effects of the 5-HT7 receptor agonist is similar to NR2B 
subunit-selective antagonist, cultures were co-pretreated with 1, 2.5 or 5 µM Ro25-6981, n = 7) 
and 300 nM LP 12 for 24 h followed by 100 µM NMDA/1 µM glycine for 10 min. The number 
of cells was determined 24 h later by MTT assay. * p < 0.05, compared to vehicle, ANOVA 
analysis with Dunnett’s post-test.
* 
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Figure 4.7 The 5-HT7 receptor activation alters NMDA receptor subunits 
expression in primary hippocampal neurons. 
A, C) Primary hippocampal neurons were incubated with vehicle or 300 nM LP 12 (LP), 1 µM 
SB 258719 (SB 25), or both for 24 h. Western blots were quantified and bands were normalized 
to the loading control β-actin. Data are expressed as the fold-change in the NR subunit expression 
vs. vehicle. NR1 (n = 9), NR2A (n = 12), NR2B (n = 14). Representive western blots are shown 
for each subunit in (B, D, F). * p < 0.05, ANOVA analysis with Dunnett’s post-test.  
	  	   	  70 
 
Figure 4.8 Inhibition of PDGFβ  receptor kinase activity blocks the LP 12-induced 
decrease in NR2B expression. 
(A, C) Primary hippocampal neurons were incubated with vehicle or 300 nM LP 12 (LP), 5 lM 
STI-571, or both for 24 h. Western blots were quantified and bands were normalized to the 
loading control ß-actin. Data are expressed as the fold change in the NR1 (A, n = 4) or NR2B (C, 
n = 7) subunit expression versus vehicle, *p < 0.05, ANOVA analysis with Dunnett’s post-test. 
Representative western blots are shown in (B and D). 
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4.5 Discussion 
There is evidence that the brain uses the PDGF system as an endogenous neuroprotective 
mechanism to counter neuronal insults. Focal ischemia in rat brain causes an increase in PDGF-B 
mRNA that peaks at 24 h post-ischemia (Iihara et al. 1996). PDGFβ receptor expression also rises 
rapidly after ischemia in rat brain (Iihara et al. 1996). In addition to PDGFβ receptor and PDGF 
ligand being upregulated after ischemic events, exogenous PDGF-BB is also neuroprotective in 
focal ischemia (Sakata et al. 1998; Arimura et al. 2012) and against glutamate- and NMDA-
induced cell death in cultured neurons (Tseng and Dichter 2005; Egawa-Tsuzuki et al. 2004; 
Beazely et al. 2009). Several studies have demonstrated that activation of synaptic pools of 
NMDA receptors promotes the phosphorylation of both cAMP-response element binding protein 
and extracellular signal-regulated kinase, and promotes cell survival, whereas the activation of 
extrasynaptic NMDA receptor pools promotes cell death (Soriano and Hardingham 2007). Others 
have suggested that it is the NMDA receptor composition, specifically the NR2 subunit, that 
dictates whether NMDA receptor activation will promote cell death (NR2B) or cell survival 
(NR2A) (Lai et al. 2011). We have previously demonstrated that PDGFβ receptors selectively 
inhibit NR2B-containing NMDA receptor currents and that PDGFβ receptor neuroprotection 
against NMDA-induced toxicity is similar to that observed with the NR2B antagonist Ro 25-6981 
(Beazely et al. 2009). In addition to the effects of PDGFβ receptors on NR2B-containing NMDA 
receptors, additional NMDA receptor-independent neuroprotective mechanisms downstream of 
PDGFβ receptors have been reported. These include the activation of the phosphoinositide 3-
kinase (PI3K)/Akt pathway (Peng et al. 2008), increased expression of glutamate transporters on 
neurons and support cells (Figiel et al. 2003), and the involvement of transient receptor potential 
(TRP) C1 and TRPC6 channels (Yao et al. 2009a; Yao et al. 2009b). 
In the current study, the kinase inhibitors STI-571 and AG1296 are able to prevent LP 12-induced 
neuroprotection and changes in NMDA receptor subunit expression. The IC50 values for the 
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inhibition of PDGFβ receptor kinase activity in vitro are in the 100-nM range; however, their 
IC50 values for inhibiting PDGFβ receptor-induced effects on, for example, cell growth, are in 
the low- to mid-µM range (Kovalenko et al. 1994; Roussidis et al. 2007; Weigel et al. 2009). We 
observed a significant effect on LP 12-induced neuroprotection at 1 µM for STI-571 and 5 µM for 
AG1296 and believe that this suggests that PDGFβ receptor kinase activity is required for the 
effects of LP 12. However the interpretation of these results is made more difficult given the 
long-term (24 h) experimental design. In the current work, LP 12 and the kinase inhibitors are co-
incubated over the entire 24 h period. To further complicate the interpretation, 5-HT7 receptors 
are being desensitized/downregulated by 300 nM LP 12 (Figure 4.1C) (Krobert et al. 2006) and 
PDGFβ receptor expression and phosphorylation state are increasing (Figures 4.1A, B). 
Additional studies will be required to determine the temporal relationship between these events. 
There is conflicting evidence for the effect(s) of 5-HT7 receptor on neuronal and synaptic 
activity. There is evidence that 5-HT7 receptors increase synaptic excitability in the hippocampus 
(Bacon and Beck 2000; Gill et al. 2002; Tokarski et al. 2005). However other reports suggest that 
5-HT7 receptors decrease glutamatergic signaling. Circadian phase advances in the dorsal raphe 
nucleus (DRN) involve an inhibition of glutamatergic neurotransmission (Duncan and Congleton 
2010) and 5-HT7 receptors in the DRN antagonize NMDA receptor-dependent synaptic release of 
both serotonin and glutamate (Harsing et al. 2004). The glutamate-mediated increase in 
intracellular calcium is inhibited by 5-HT7 receptor activation in rat SCN (Smith et al. 2001) and 
the amplitude of glutamate excitatory postsynaptic potentials (EPSPs) is decreased after 5-HT7 
receptor activation in mouse suprachiasmatic nucleus (Quintero and McMahon 1999). Recently, 
Kobe et al. demonstrated that the activation of 5-HT7 receptors increased the number of dendrites 
and promoted synapse formation in primary hippocampal cultures, but did not affect the 
magnitude of long-term potentiation (LTP). However, 5-HT7 receptor knock-out mice display a 
reduced induction of LTP (Roberts et al. 2004). 5-HT7 regulation of PDGFβ receptor expression 
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may explain the lack of clarity with respect to the effects of 5-HT7 receptors on glutamatergic 
signaling. In some of the studies cited above, 5-HT7 receptor agonists were applied for 5-10 min 
(Harsing et al. 2004; Quintero and McMahon 1999) whereas in other animals or tissues studies 
the treatment time ranged from hours to days, a time period sufficient for the upregulation of 
PDGFβ receptors (Duncan and Congleton 2010; Kobe et al. 2012). Furthermore, none of the 
studies cited above used selective 5-HT7 agonists and only Kobe et al. used a selective 5-HT7 
receptor antagonist in their study.  
5-HT7 receptors display inverse agonist responses when treated with several antagonists (Romero 
et al. 2006). Furthermore, 5-HT7 receptors are rapidly desensitized in recombinant systems by 
both agonists and antagonists (Krobert et al. 2006) and indeed we saw a robust reduction in 5-
HT7 receptor expression after prolonged exposure to the 5-HT7 receptor agonist, LP 12. Several 
antipsychotic agents with affinities for the 5-HT7 receptor, including respiridone, appear to 
“inactivate” 5-HT7 receptors (as measured by 5-HT-stimulated cyclic AMP accumulation in 5-
HT7 receptor-expressing cells) after a brief exposure to these agents (Toohey et al. 2009). 
Toohey et al. (2009) hypothesize that these neuroleptics induce a stable 5-HT7 conformation that 
prevents receptor activation of Gαs. However, in this study the neutral antagonist, SB 258719 did 
not change PDGFβ receptor or NMDA receptor expression after when used alone. Similarly, in 
our previous work examining the effects of LP 12 on promoting PDGFβ receptor expression, 
neither of the 5-HT7 receptor antagonists used altered PDGFβ receptor expression when used 
alone (Vasefi et al. 2012). 
Notwithstanding the effectiveness of growth factors to protect neurons against a variety of insults 
in vitro (Beazely et al. 2009) and in animal models (Wu et al. 2004), there are several obstacles 
that prevent their clinical use. For example, growth factors such as PDGF are several tens of 
kilodaltons in size and do not readily cross the blood-brain barrier. Certain growth factors 
including PDGF may increase the risk of glioma induction or proliferation (Shih and Holland 
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2006; Ellis et al. 2011; Ellis et al. 2012b; Ellis et al. 2012a). Furthermore, PDGF causes several 
direct effects on the vasculature, including cerebral vasospasm in rats (Shiba et al. 2013). Could 
these obstacles be avoided by promoting the signaling of endogenous growth factors and their 
receptors in situ, rather than attempting to introduce exogenous proteins into the brain? Our 
results demonstrate that 5-HT7 receptor activation not only increased the expression of PDGFβ 
receptors, but also increased the expression of PLCγ and caused a down-regulation of 5-HT7 
receptors in primary hippocampal neurons. We demonstrated that long-term (24 h) activation of 
5-HT7 receptors resulted in neuroprotective effects against NMDA-induced toxicity and that this 
effect was PDGFβ receptor-dependent (Figure 4.9). Furthermore, 5-HT7 agonists selectively 
decreased the expression of the NR2B and NR1 subunits of the NMDA receptor. The findings 
suggest that targeting GPCRs may be a valid strategy to exploit the neuroprotective effects of 
growth factor receptors in neurons.  




Figure 4.9 Schematic displaying the proposed pathway whereby 5-HT7 receptor 
agonists provide neuroprotection against NMDA toxicity via their effects on 
PDGFβ  receptor-expression. 
Long-term (24 h) activation of 5-HT7 receptors increases the expression of PDGFβ receptors and 
PLCγ as well as an increase in the PLCγ-activating site on the PDGFβ receptor, Y1021 (green 
circle). 5-HT7 receptor activation prevents NMDA-induced toxicity and differentially regulates 
NMDA receptor subunit expression: NR1 and NR2B subunit expression is reduced but NR2A 
subunit expression remains unchanged. Both the neuroprotective effects and the effects on 
NMDA receptor subunit expression induced by 5-HT7 agonists are blocked by PDGFβ receptor 
kinase inhibitors.




Twenty percent of Canadians will experience a mental illness during their lifetime (Public Health 
Agency of Canada, 2012). The 5-HT7 receptor may represent a useful pharmacological target for 
the treatment of psychiatric disorders such as schizophrenia and depression (Nikiforuk 2012). 
Schizophrenia affects 1% of the Canadian population (Perala et al. 2007). Current medication 
includes antagonists of the dopamine D2 receptor: antipsychotic drugs that prevent the positive 
symptoms of this disease and are much less effective at treating the negative or cognitive 
symptoms (Ritsner and Kurs 2002). A medical need exists for additional progress in the treatment 
of schizophrenia. A number of antipsychotic drugs have a high affinity for 5-HT7 receptors, 
which indicates the possibility that some of the effects of these drugs could be mediated by 5-
HT7 receptors (Leopoldo et al. 2011). Pharmacological studies indicate that 5-HT7 receptor 
antagonists demonstrate both antipsychotic and pro-cognitive activity in preclinical animal 
models and thus may have therapeutic potential for use in the treatment of schizophrenia 
(Horisawa et al. 2013; Waters et al. 2012); however, the potential role of 5-HT7 receptors is 
unclear.  
5.1 5-HT7 receptor neuroprotection 
5.1.1 Long-term (24 h) activation of 5-HT7 receptors 
PDGFβ receptors play an important role in mitogenic signaling pathways; however, direct and 
prolonged activation of PDGFβ receptors leads to hyperplasia and cancer (Heldin and 
Westermark 1999). Nevertheless, activation of PDGFβ receptors after 24 h 5-HT7 agonist 
treatment is neuroprotective via PDGFβ receptor. The question is whether it would be possible to 
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achieve the beneficial, neuroprotective effects of PDGFβ receptor signaling while avoiding 
potential unregulated cell growth. 
In addition to long-term (24 h) 5-HT7 receptor-induced upregulation of PDGFβ receptors and an 
increase in their basal phosphorylation state, PDGFß receptors can also be acutely transactivated 
by GPCRs such as the dopamine receptor D4 (Nair and Sealfon 2003; Oak et al. 2001). ERK1/2 
activity promotes cell survival and proliferation and PDGFβ receptors activate ERK1/2 (Heldin 
and Westermark 1999). Dopamine D4 and D2 receptors increase ERK1/2 activity in Chinese 
hamster ovary CHO-K1 cells (Oak et al. 2001). However, Oak et al. (2001) determined that 
dopamine-induced ERK1/2 activity was blocked by selective tyrosine kinase inhibitors AG1295 
and tyrphostin A9 (Oak et al. 2001). This finding demonstrates that dopamine transactivates 
PDGFβ receptors and that dopamine receptor-induced ERK1/2 activity is dependent on PDGFβ 
receptor activity in the CHO cells (Oak et al. 2001). 
A recent publication from our lab demonstrated that 5-CT is able to acutely transactivate the 
PDGFβ receptor; however, this effect was mediated by 5-HT1A, not 5-HT7, receptors (Kruk et 
al. 2013b). In hippocampal cultures, the expression of PDGFβ receptors was increased by 5-CT 
after 24 h treatment, and the maximal effect was observed at a concentration of 50 nM (Figure 
2.1). 5-CT activates 5-HT1, 5-HT5, and 5-HT7 receptors; however, the expression of PDGFβ 
receptors was not blocked by WAY 100635, a 5-HT1A receptor antagonist (Figure 3.2). Rather, 
the WAY 100635 compound actually potentiated the effects of 5-CT. The ability of WAY 
100635 to act as a potent dopamine receptor agonist (in HEK 293 cells) may explain the 
increased level of PDGFβ receptor expression created by WAY 100635 (Wenk 2003).  
The 5-HT7 receptor increases cAMP formation via Gαs protein (Bard et al. 1993; Lovenberg et 
al. 1993; Adham et al. 1998). Activation of the 5-HT7 receptor increases cAMP levels in rabbit 
and human corneal epithelium (Neufeld et al. 1982; Crider et al. 2003). This effect is blocked by 
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SB269970, a selective 5-HT7 receptor antagonist (Grueb et al. 2012). 5-HT4 and 5-HT6 
receptors increase cAMP levels as well; however, it is likely that the cAMP formation observed is 
via the 5-HT7 receptor because the 5-HT4 and 5-HT6 receptors are not expressed in the corneal 
epithelium and the effects are blocked by SB269970 (Pauwels 2000; Crider et al. 2003). The 
stimulation of 5-HT7 receptors with 5-CT is also positively coupled to the cAMP and PKA 
formation in corneal epithelial and endothelial cells (Grueb et al. 2012). In our studies, the PKA 
inhibitor H89 blocked 5-CT-mediated increases in the expression of the PDGFβ receptor, an 
effect that suggests that the Gαs pathway is responsible for the increased expression of PDGFβ 
receptors in hippocampal neurons (Figure 3.2). 
5-CT activates 5-HT1 (Gαi/o-coupled), 5-HT5 (Gαi/o-coupled), and 5-HT7 (Gαs-coupled) 
receptors; however, our pathway suggests that 5-CT increases PDGFβ receptor expression 
through a Gαs-coupled receptor. The selective 5-HT7 receptor agonist LP 12 increases the 
expression of PDGFβ receptors in hippocampal and cortical neuron cultures and in an SH-SY5Y 
cell line after 24 h, and this effect is blocked by both 5-HT7 receptor antagonists: SB 269970 and 
SB 258719 (Figure 3.4). 
Figure 3.4C (rt-PCR experiment) suggests that the expression level of the PDGFβ gene and the 
mRNA level of the PDGFβ receptor were both increased significantly in a primary hippocampal 
culture after treatment with LP 12 for 24 h. In addition to the LP 12-mediated increase in 
expression, LP 12 treatment also increases PDGFβ receptor phosphorylation at tyrosine (Y) 1021, 
the PLCγ binding site (Figure 3.8). The phosphorylation of Y1021 is associated with the 
inhibition of the NMDA receptor (Beazely et al. 2009; Lei et al. 1999; Valenzuela et al. 1996), 
and phosphorylation of this site is increased after dopamine receptor transactivation of the 
PDGFβ receptor and subsequent inhibition of NMDA-evoked currents in hippocampal and 
cortical slices (Kotecha et al. 2002; Beazely et al. 2006). 
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Reduced levels of 5-HT7 receptors in spinal nerve injury suggest that selective 5-HT7 receptor 
antagonists may act as analgesics with respect to nerve injury pain (Amaya-Castellanos et al. 
2011). However, none of the studies used selective 5-HT7 receptor ligands or investigated the 
effects of long-term (> 24 h) treatment. Krobert et al. (2006) reported that 5-HT7 receptor 
signaling was desensitized by both agonists and antagonists (Krobert et al. 2006). The data 
presented in this work indicate that long-term (24 h) treatment with LP 12 upregulates PDGFβ 
receptor expression and activation but downregulates 5-HT7 receptor expression in a mouse 
hippocampal culture (Figure 4.1). This finding suggests that long-term treatment with a 5-HT7 
receptor agonist might alleviate pain by downregulating the 5-HT7 receptor.  
PDGF-BB protects neurons from NMDA-induced cell death (Beazely et al. 2006), and the PDGF 
system may decrease the risk of ischemic brain injury (Egawa-Tsuzuki et al. 2004). To identify 
whether 5-HT7 upregulated from PDGFβ receptors was neuroprotective, primary cultures were 
treated with LP 12 followed by NMDA/glycine treatment. The results show that LP 12 treatment 
did indeed prevent NMDA-induced cell death and that the neuroprotective effect of LP 12 was 
blocked by STI-571 and AG1296, two PDGFβ receptor kinase inhibitors (Figure 4.5). 
PDGFβ receptors are expressed in primary hippocampal neurons (Smits et al. 2001; Beazely et 
al. 2009). Growth factors and neurotrophic factors, as therapeutic agents, cannot permeate the 
blood-brain barrier (BBB) because of their size, and they cannot be administered orally because 
of degradation in the gastrointestinal tract. In addition, hyperplasia and cancer might be promoted 
by high doses of exogenous growth factors such as PDGF (Heldin and Westermark 1999). Small 
molecules that can activate GPCRs and transactive PDGFβ receptors can permeate the BBB 
(Hardebo and Owman 1980). Treatment with LP 12 for 24 h increased the PDGFβ receptors on 
both neuronal cell bodies and cell processes but not on non-neuronal cells (Figure 4.4). 5-HT7 
receptor ligands also increased the phosphorylation of PDGFβ receptors at Y1021 in neurons. 
However, the magnitude of the increase in PDGFβ receptor expression and phosphorylation may 
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not be great enough to cause hyperplasia and cancer. Thus, GPCR promotion of PDGFβ receptor 
signaling may allow for in situ promotion of PDGFβ receptor activity without many of the 
adverse consequences. These findings suggest that targeting GPCRs may be a strategy for 
exploiting the neuroprotective effects of growth factor receptors in neurons.  
The findings of this research represent key contributions to the field of 5-HT receptor regulation 
of NMDA receptor activity. All 5-HT receptor subtypes have been reported to regulate NMDA 
receptors (Marcos et al. 2010). NMDA receptor activation is inhibited by the function of 5-HT1A 
receptors in several regions of the brain (Licata et al. 1998; Murase et al. 1990; Schmitz et al. 
1995; Strosznajder et al. 1996; Yuen et al. 2008). The activation of 5-HT1 receptors leads to the 
inhibition of presynaptic glutamatergic transmission in the spinal cords of rats (Singer et al. 
1996). 5-HT also increases the basal neuronal firing rate through the activation of 5-HT2 
receptors and decreases the firing rate through the activation of 5-HT1 receptors (Licata et al. 
1995). The 5-HT2B receptor is involved in presynaptic inhibition and causes several behavioural 
effects in the CNS. The activation of 5-HT2 receptors appears to facilitate NMDA-induced 
membrane depolarization; the evidence suggests that it enhances phosphoinositide hydrolysis, 
which leads to the production of IP3, DAG, and Ca2+ (Berridge 1987; Chuang 1989; Nahorski 
1988). The depolarization of NMDA using the grease-gap recording technique is enhanced by 5-
HT through the action of 5-HT2 receptors (Rahman and Neuman 1993), and the effect of 5-HT2 
receptors on NMDA depolarization has been examined using the agonist of 2,5-dimethoxy-4-
iodoamphetamine (DOI) that is selective for the 5-HT1C and 5-HT2 agonist, m-
trifluromethylpiperazxine (TEMPP), a 5-HT1B and 5-HT1C agonist, and 8-OH-DPAT, a 5-
HT1A agonist. 
The 5-HT4 receptor increases cAMP levels and is expressed in the hippocampal, cortical, and 
striatal regions. This evidence suggests that 5-HT4 has an indirect effect on NMDA receptors. 5-
HT4 receptors play an important role in the regulation of the release of hippocampal 
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acetylcholine (King et al. 2008), and their activation induces neuronal excitability (Ansanay et al. 
1996; Bockaert et al. 1998). 
Several studies have shown that 5-HT6 receptors are involved in learning and memory (Woods et 
al. 2012; Fone 2008). The activation of the 5-HT6 receptor also alters NMDA receptor subunit 
expression in the striatum in a learning model (Marcos et al. 2010). The psychotomimetic effects 
of the NMDA receptor antagonist are attenuated by the 5-HT6 receptor antagonist (Pitsikas et al. 
2008). 
NR2A subunits are expressed primarily in the synaptic area and are associated with glutamate-
induced neuroprotection. NR2B subunits are expressed in the extrasynaptic area and are related to 
glutamate-mediated hippocampal toxicity (Beazely et al. 2009). PDGFβ receptors do not 
significantly colocalize with PSD-95, a synaptic marker, or with the NR2A subunit of NMDA 
receptors (Beazely et al. 2009), suggesting that their expression is primarily extrasynaptic. 
Prolonged treatment with a 5-HT7 receptor agonist changes the expression and the 
phosphorylation profile of NMDA receptor subunits. 5-HT7 receptor activation reduced the 
expression of NR1 and NR2B subunits, and this effect was blocked by SB 258719 and STI-571 
(Figures 4.7, 4.8). These results suggest that the neuroprotective effect of LP 12 requires the 
kinase activity of the PDGFβ receptor and that the 5-HT7 receptor may be colocalized with the 
PDGFβ receptor and the NR2B-containing NMDA receptor in the extrasynaptic area. Ro 25-
6981, an NR2B subunit-selective antagonist, elicits a neuroprotective effect similar to that 
produced by LP 12 (Figure 4.6).  
In addition to increasing PDGFβ receptor expression, LP 12 treatment also increased the 
expression of PLCγ in hippocampal cultures (Figure 4.2). Interestingly, the phosphorylation of 
the PDGFβ receptor at Y1021, the primary PLC γ binding and activation site, is required for the 
neuroprotective effect of PDGFβ receptors against NMDA-induced cell death (Figure 4.9) 
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(Beazely et al. 2009). Activation of PDGF receptors leads to a decrease in the NMDA-evoked 
current in hippocampal neurons (Valenzuela et al. 1996; Lei et al. 1999), and recombinant 
PDGFβ receptors also inhibit NMDA-evoked currents in oocytes (Valenzuela et al. 1996). A PLC 
inhibitor abolished the depression of the NMDA current in hippocampal neurons after treatment 
with PDGF-BB or quinpirole (Lei et al. 1999; Kotecha et al. 2002). Neuregulin receptor tyrosine 
kinase activation has also been reported to inhibit NMDA currents by activating a PLC-dependent 
pathway (Gu et al. 2005). These data suggest that the activation of PDGFβ receptors at Y1021 by 
5-HT7 receptors may decrease NMDA currents in hippocampal neurons. Further experiments 
should involve an analysis of NMDA-evoked currents in neurons after LP 12 treatment. 
NMDA receptors can either kill neurons or support neuronal health (Hardingham and Bading 
2010). Activation of all NMDA receptors results in ERK activation followed by ERK inactivation 
(Chandler et al. 2001). Activation of synaptic NMDA receptors promotes ERK signaling pathway 
and increases the phosphorylation of the transcription factor CREB to promote neuroprotection 
(Hetman and Kharebava 2006). Extrasynaptic NMDA receptor activation induces the 
deactivation of ERK and CREB in hippocampal and cortical neurons and leads to 
neurodegeneration (Zhang et al. 2007). 5-HT7 receptor agonist treatment (24 h) increases both 
ERK and CREB expression (Figure 3.3), and these may also contribute to the neuroprotective 
effect of PDGF receptors in hippocampal cultures. PDGFβ receptors directly increase the 
phosphorylation of ERK and indirectly decrease the ability of NR2B subunits to promote ERK 
and CREB dephosphorylation (Beazely et al. 2009). The increased level of ERK and CREB 
expression through the activation of 5-HT7 receptors may be a result of the downregulation of 
NR2B-containing NMDA receptors in a hippocampal neuron culture.  
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5.1.2 Acute (5 min to 10 min) activation of 5-HT7 receptors 
In contrast to the long-term activation of 5-HT7 receptors, acute 5-CT treatment (5 min) increases 
NMDA-evoked currents in hippocampal neurons, and this effect has been shown to be blocked by 
5-HT7 receptor antagonists (Vasefi et al. 2013b). The application of 5-CT and LP 12 increases 
NR1 receptor phosphorylation at serine 897 and serine 896 (Figure 2.1). Increases in the serine 
897 PKA phosphorylation site and the serine 896 PKC phosphorylation were blocked by H89 or 
Go6083, respectively (Figure 2.1). Acute activation of 5-HT7 receptors promotes NMDA 
receptor phosphorylation and evoked currents in the hippocampal slices. However, long-term 
treatment with LP 12 decreases NMDA receptor expression through tyrosine kinase activity. 
While 5-HT7 receptor agonists have been found to promote pain after formalin injections in 
animal models (Rocha-Gonzalez et al. 2005), others have reported that 5-HT7 receptors produce 
anti-nociceptive effects (Dogrul and Seyrek 2006). On the other hand, the phosphorylation of 
NR2B at Y1472 is linked to spinal pain transmission (Katano et al. 2011). In our experiments, 
treatment with LP 12 acutely induced NR2B phosphorylation at Y1472 (Figure 2.3) and reduced 
NR2A subunit phosphorylation (Figure 2.3). The 5-HT7 receptor antagonist SB 258719 inhibited 
these changes in NR2 subunit phosphorylation. LP 12 also reduced surface expressions of NR2B 
in hippocampal slices (Figure 2.4). This finding suggests that the acute activation of 5-HT7 
receptors could be linked to pain transmission through the promotion of the phosphorylation of 
Y1472; however, the level of NR2B surface expression is decreased in the hippocampus. On the 
other hand, the long-term activation of 5-HT7 receptors could help reduce pain by decreasing the 
level of 5-HT7 receptors in neurons.  
5.2 Conclusions 
In contrast to the long-term activation of 5-HT7 receptors, acute activation (minutes) of 5-HT7 
receptors robustly enhances NMDA-evoked currents in isolated hippocampal neurons. Thus, 5-
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HT7 receptors regulate NMDA receptors differently depending on short-term activation vs. long-
term agonist treatment (Figure 2.5). The prolonged activation of 5-HT7 receptors may inhibit 
NMDA receptor function by decreasing NMDA receptor expression and upregulating PDGFβ 
receptors, a potent negative regulator of NMDA signaling. With respect to ischemic neuronal 
damage, PDGFβ receptor activation reduces neuronal death and enhances cell proliferation. This 
research revealed that LP 12, a selective 5-HT7 receptor agonist, provides a neuroprotective 
effect through the inhibition of NMDA-induced cell death. These findings highlight the potential 
for temporally differential regulation of NMDA receptors by 5-HT7 receptors. 
This research represents a significant advance in the ongoing quest for effective treatments for 
mental health disorders such as schizophrenia and will improve the efficient use of drug therapies 
to strengthen the overall health of patients. 5-HT7 receptor ligands could possibly be used to treat 
a number of mental health diseases, including schizophrenia. The present study involved the 
identification of molecular mechanisms and pathways for neuroprotection after 5-HT7-induced 
PDGFβ receptor upregulation and the regulation of NMDA receptor activity. Prolonged (24 h) 
activation of 5-HT7 receptors increases the expression and activation of PDGFβ receptors at 
tyrosine 1021, the PLCγ binding site. Such long-term activation of 5-HT7 receptors offers 
neuroprotective benefits by increasing the expression of a negative regulator of NMDA activity: 
the PDGFβ receptor. In addition, activation of the 5-HT7 receptor also selectively changes the 
expression and phosphorylation state of the NR2B subunit of the NMDA receptor. Interestingly, 
acute activation (5 min) of 5-HT7 receptors altered NMDA receptor subunit phosphorylation and 
increased NMDA-evoked currents in the hippocampal neurons. Thus, two distinct 5-HT7 
receptor-NMDA receptor regulatory mechanisms have been identified: acute activation of the 
receptor increased NMDA-evoked currents whereas long-term 5-HT7 agonist treatment 
prevented NMDA-induced excitotoxicity in a PDGFβ receptor-dependent manner. These findings 
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may help to explain why previous reports have identified 5-HT7 receptors as both positive and 
negative regulators of NMDA receptor signaling. 
5.3 Future direction and considerations 
5.3.1  NMDA receptor currents 
The electrophysiology data demonstrate that 5-CT increased NMDA-evoked currents (5 min to 
30 min) (Vasefi et al. 2013b). However, long-term LP 12 activation decreased NR2B-containing 
NMDA receptor expression in the hippocampal culture. It would be interesting to measure 
NMDA receptor miniature excitatory postsynaptic currents (mEPSCs) in hippocampal cultures 
subjected to 24 h LP 12 treatment. Measuring these currents during 24 h LP 12 incubation would 
also help to identify whether 5-HT7 receptors switch from promoting to inhibiting NMDA 
receptor activity over time.  
With the use of the MTT assay, this research has demonstrated that, after 24 h treatment with LP 
12, 5-HT7 receptors have a neuroprotective effect against NMDA. The results indicate that 5-CT 
and 5-HT7 receptors increase the expression and activation of PDGF receptors as early as 2 h. 
The 5-HT7 receptor activation could be neuroprotecive from 2 h to 12 h of a 24 h incubation. For 
future investigation, shorter-term cell survival experiments would help to determine how long an 
incubation with 5-HT7 ligands would be required in order to provide neuroprotection. 
In all of the above experiments, cells were treated with LP 12 for 24 h and NMDA was applied 
for 5 min. It would be interesting to treat the cells with NMDA prior to LP 12 treatment and the 
measure the neuroprotective effect of LP 12 in the neuron culture. The results of this experiment 
would help predict whether 5-HT7 receptor activation could improve post-injury neuronal health.  
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Appendix A 
Supplementary Data 
This appendix contains additional data of interest. Some these data are negative results or data that 
were the result of collaboration with other research groups. 
NMDA 
NMDA receptors are important in the pathogenesis of schizophrenia (Tolis et al. 2002). The NMDA 
glutamate receptor, a main subtype of the excitatory ligand-gated ion channel, has been implicated in 
multiple neuronal functions such as learning and memory (Dingledine et al. 1999).  
	  
Figure Apx A. 1 NMDA–induced cell death in hippocampal cultures. 
NMDA was used to induce cell death in a neuron culture. NMDA could kill SH-SY5Y cells, 
hippocampal and cortical cultures from 100 µM to 1 mM for 5 min. The hippocampal cultures were 
treated with 100 µM, 300 µM, and 500 µM of NMDA for 5 min. The number of live cells was 
counted using the MTT and MAP2 test.  ***p < 0.001, ANOVA analysis with Duunett’s post-test.
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β-amyloid	  
Alzheimer disease (AD) is a neurodegenerative disease in which β-amyloid plaque formation causes a 
decline in cognitive function and memory. β-amyloid plaque is toxic and responsible for pathological 
effects of AD (Wenk 2003). The following experiments were conducted in collaboration with Hui 
(Lucy) Liu and Dr. Zoya Leonenko. The results determined that β-amyloid attenuates the 
neuroprotective effects of PDGF and LP 12 against NMDA-induced excitotoxicity. I also measured 
the neuroprotective effects of melatonin (M) and cyclodextrin (CD) against β-amyloid toxicity. 
Interaction between β-amyloid and PDGF-BB 
	  
Figure Apx A. 2 β-amyloid inhibits PDGF-BB neuroprotection against NMDA-induced 
excitotoxicity. 
To determine whether PDGF-BB was neuroprotective against β-amyloid, the SH-SY5Y cells were 
treated with the vehicle or 5 µM of β-amyloid (Aß) for 10 min followed by 50 ng of PDGF-BB for 10 
min. For the test represented by the NMDA bar in the figure, 100 µM NMDA/1 µM glycine was 
added for10 min after PDGF-BB treatment. Cells were incubated with fresh serum-free media. The 
number of cells was determined 24 h later by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. PDGF-BB for 10 min reduced NMDA-induced cell death, and this effect was 
blocked by β-amyloid in the cell culture. **p < 0.01, vehicle versus NMDA, # p < 0.05, NMDA 
versus NMDA + PDGF-BB, ANOVA analysis with Bonferroni’s post-test.
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β-amyloid and LP 12 	  
	  	  
Figure Apx A. 3 β-amyloid attenuates LP 12 neuroprotection in the cell cultures. 
These data indicate that LP 12 (24 h treatment) was neuroprotective against NMDA-induced toxicity 
in a hippocampal culture. To determine whether LP 12 was neuroprotective against β-amyloid, the 
SH-SY5Y cells (A) and RGC cells (B) were treated for 10 min with β-amyloid (5 uM), followed by 
24 h of LP 12 (300 nM). Cells were incubated with fresh serum-free media. The number of cells was 
determined 24 h later by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
LP 12 could not protect the cells against β-amyloid. **p < 0.01, ANOVA analysis with Bonferroni’s 
post-test.
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β-amyloid and melatonin/cyclodextrin 
 
Figure Apx A. 4 Melatonin is neuroprotective against β-amyloid. 
To evaluate whether melatonin (M) and cyclodextrin (CD) are neuroprotective against β-amyloid 
(Aß), the RGC cells were treated with 5 uM CD for 1 h. RGC cells were washed and added 5 µM β-
amyloid for 2 h (A) and 24 h (B). Melatonin 50 uM were added 45 min prior to β-amyloid treatment. 
Melatonin was able to protect the RGC cells against β-amyloid. n = 8 *p < 0.05, ANOVA analysis 
with Bonferroni’s post-test.
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Hydrogen peroxide 
In previous studies, oxidative stress was shown to be involved in the death of RGC cells and to be 
associated with ocular neurodegenerative disorders (Li et al. 2012). It has also been reported that a 
high level of hydrogen peroxide (H2O2) caused cellular damage and cell death (Burton and Jauniaux 
2011). However, D1 dopamine receptor agonists reduced H2O2-induced injury in RGC cells (Li et al. 
2012). This section describes our examination of whether the 5-HT7 receptor agonist LP 12 can 
attenuate H2O2 toxicity in RGC cells. These experiments were conducted in collaboration with 
Anshula Samarajeewa in order to determine whether LP 12 is neuroprotective against H2O2-induced 
cell death. 
H2O2 and RGC cells 
	  
Figure Apx A. 5 H2O2–induced toxicity in RGC cells.  
RGC cells were incubated with H2O2 (50 µM to 500 mM) for 30 min, followed by an MTT assay to 
measure the cell viability in the culture. H2O2 toxicity occurred in a dose-dependent manner. N = 8 * 
p < 0.05, ANOVA analysis with Bonferroni’s post-test.
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H2O2 and LP 12 
	  
 
Figure Apx A. 6 LP 12 did not affect H2O2-induced cell death. 
RGC cells were incubated with vehicle or H2O2 (30 min) and 300 nM LP 12 (24 h), or both. The 
number of live cells was measured using an MTT assay. These results indicate that LP 12 did not 
protect RGC cells against H2O2. n = 8, ANOVA analysis with Bonferroni’s post-test. 
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Appendix B 
Research Activity Resulting from this program 
• Selected Refereed Reports 
Jeff Kruk, Maryam S. Vasefi, J. J. Heikkila, and M. A. Beazely. “Reactive oxygen species are 
required for 5-HT-induced transactivation of neuronal platelet-derived growth factor and TrkB 
receptors but not for ERK1/2 activation,” PLOS ONE, 2013. 
Maryam S. Vasefi, Kai Yang, Jerry Li, J. Kruk, J. J. Heikkila, M. F. Jackson, J. F. MacDonald, and 
M. A. Beazely. “5-HT7 receptor activation increases NMDA-evoked currents in isolated hippocampal 
neurons,” Molecular Brain, 2013. 
M. S. Vasefi, J. Kruk, J. J. Heikkila, and M. A. Beazely. “5-HT7 receptor-mediated neuroprotection 
against NMDA–induced excitotoxicity is PDGFß receptor-dependent,” Journal of Neurochemistry, 
2013. 
J. Kruk, M. S. Vasefi, H. Liu, J. Heikkila, and M. A. Beazely. “5-HT1A receptors transactivate the 
platelet-derived growth factor receptor type beta in neuronal cells,” Journal of Cellular Signaling, 
2013. 
Tarek Mohamed, Jacky Yeung, Maryam S. Vasefi, Michael A. Beazely, and Praveen P. Rao. 
“Development and evaluation of multifunctional agents for potential treatment of Alzheimer’s 
disease: Application to a pyrimidine-2,4-diamine template,” Bioorganic & Medicinal Chemistry 
Letters, 2012. 
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M. S. Vasefi, J. Kruk, H. Liu, M. A. Beazely, and J. J. Heikkila. “Activation of 5-HT7 receptors 
increases neuronal platelet-derived growth factor ß receptor expression,” Neuroscience Letters, 2012. 
	  
• Articles in Progress or Submitted for Publication  
Jeff Kruk, Maryam S. Vasefi, J. J. Heikkila, and M. A. Beazely. “Fluoxetine-induced transactivation 
of the platelet-derived growth factor type β via serotonin receptors reveals a heterologous 
desensitization mechanism,” Molecular and Cellular Neuroscience (submitted). 
Maryam S. Vasefi, and Micheal Beazely. “Serotonin receptor subtype regulation of N-methyl-D-
aspartate receptors,” Brain Research (in progress). 
Hui Liu, Golam T. Saffi, Maryam S. Vasefi, Zoya Leonenko, Vince Choi, Jeff S. Kruk, and Michael 
A. Beazely. “The inability of PDGF-BB to protect neuronal cells from β-amyloid toxicity reveals a 
novel mechanism of β-amyloid toxicity” (in progress). 
Lollita Goldman, Ansula Samarajeewa, Maryam S. Vasefi, Azita Koshmashki, Chandi….. “5-HT7 
receptors upregulates TrkB in neuron models” (in progress). 
 
• Selected Poster Presentations 
Maryam S. Vasefi, and Michael A. Beazely. “Regulation of NMDA receptors by 5-HT7 receptor 
ligands,” SONA conference, University of Waterloo, Waterloo, May 13, 2013. 
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Anshula Samarajeewa, Azita Kouchmeshky, Maryam S. Vasefi, and Michael A. Beazely. 
“Prospective intervention for Glaucoma: 5-HT7 receptor activation increases TRKB expression and 
phosphorylation,” SONA conference, University of Waterloo, Waterloo, May 13, 2013. 
Jeff S. Kruk, Maryam S. Vasefi, John J. Heikkila, and Michael A. Beazely. “Transactivation of 
platelet-derived growth factor type beta receptors is subject to heterologous desensitization in 
neuronal culture,” SONA conference, University of Waterloo, May 13, 2013. 
Maryam S. Vasefi and Michael A. Beazely. “5-HT7 receptor-induced neuroprotection is PDGF 
receptor-dependent,” Great Lakes GPCR Retreat conference, London, October 17-19, 2012. 
Jeff J. Kruk, Maryam S. Vasefi, and Michael A. Beazely. “Monoamine transporter inhibitors can 
transactivate the platelet-derive growth factor receptor type beta in neuronal cells,” Great Lakes 
GPCR Retreat conference, London, October 17-19, 2012. 
Maryam S. Vasefi, Kai Yang, and Michael A. Beazely. “5-HT7 receptor neuroprotection against 
excitotoxicity in the hippocampus,” AFPC, Quebec City, June 2012. 
S. M. Vasefi and M. Beazely. “5-HT7 receptor neuroprotection against excitotoxicity in the 
hippocampus.” CREST, McMaster University, Hamilton, March 11-12, 2011. 
Jerry Li, Maryam S. Vasefi, and Michael A. Beazely. “Serotonin receptor type 7 regulation of 
NMDA receptor subunit phosphorylation in the hippocampus,” School of Pharmacy, University of 
Waterloo, Kitchener, 2010.  
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M. A. Beazely, S. M. Vasefi, J. Kruk, and K. Yang. “Bidirectional regulation of NMDA receptor 
signaling by type 7 seretonin receptors,” First Presenter, Great Lakes GPCR Retreat conference, 
University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, 2010.  
 
• Non-Refereed Contributions 
S. M. Vasefi. “Bidirectional regulation of NMDA receptor signaling by type 7 serotonin receptors,” 
University of Waterloo Graduate Student Research Conference, Waterloo, April 27, 2011. 
S. M Vasefi. “5-HT7 receptor neuroprotection against excitotoxicity in the hippocampus,” Ph.D. 
research proposal presentation, University of Waterloo, Waterloo, 2010. 
S. M Vasefi. “Regulation of PDGF receptor expression by 5-HT type 7 receptors: A mechanism for 
an indirect inhibition of NMDA receptor signaling?” School of Pharmacy Journal Club presentation, 
University of Waterloo, Kitchener, 2010.
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Appendix C 
Copyright details  
Elsevier 
At Elsevier, we request transfers of copyright, or in some cases exclusive rights, from our journal 
authors in order to ensure that we have the rights necessary for the proper administration of electronic 
rights and online dissemination of journal articles. Authors and their employers retain (or are 
granted/transferred back) significant scholarly rights in their work. We take seriously our 
responsibility as the steward of the online record to ensure the integrity of scholarly works and the 
sustainability of journal business models, and we actively monitor and pursue unauthorized and 
unsubscribed uses and re-distribution (for subscription models). 
	  
Molecular Brain  
All articles published by Molecular Brain are made freely and permanently accessible online 
immediately upon publication, without subscription charges or registration barriers... Authors of 
articles published in Molecular Brain are the copyright holders of their articles and have granted to 
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any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, 
according to the BioMed Central copyright and license agreement.  
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Contributors may use the articles in teaching duties and in other works such as theses. 
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